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ABSTRACT 
THE FUNCTION OF SETD5 AND MIR-221  
IN EMBRYONIC STEM CELL DIFFERENTIATION 
Tsai-Yu Chen, M.S. 
 
Advisory Professor: Min Gyu Lee, Ph.D. 
 
Embryonic stem cells (ESCs) are a widely used model system to study cellular 
differentiation because of their pluripotent characteristics, and ESC differentiation is an epigenetic 
process. In an effort to identify a new epigenetic factor that is required for ESC differentiation, 
the function of SETD5 in ESCs was studied for this thesis. Results show that SETD5 is essential 
for retinoic acid (RA)-induced differentiation of mouse ESCs and for RA-induced expression of 
critical developmental genes (e.g., Hoxa1 and Hoxa2) and neuron-related genes (e.g., Nestin and 
Pax6). SETD5 was upregulated during ESC differentiation. Additional results demonstrated that 
SETD5 bound to RAR-α upon RA treatment and was recruited to a retinoic acid response element 
(RARE) for Hoxa1 and Hoxa2 activation. Methyltransferase assay using recombinant SETD5 and 
SETD5 complex showed that SETD5 was catalytically inactive, although it has a putative 
catalytic domain called SET. The transcription coactivator HCF1 was identified as a major 
SETD5-interacting protein. Depletion of HCF1 inhibited RA-induced ESC differentiation and 
RA-induced expression of SETD5-regulated genes. Chromatin immunoprecipitation assay 
provided evidence that HCF1 was localized to the SETD5-bound RARE region after RA treatment. 
These findings reveal a previously unknown ESC differentiation mechanism in which SETD5 
facilitates mouse ESC differentiation by activating differentiation-specific genes via cooperation 
with HCF1. 
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In a related but independent study, we show that miR-221-3p and miR-221-5p, which are 
encoded by the miR-221 gene, are new anti-stemness miRNAs whose expression levels in mouse 
ESCs are directly repressed by the epigenetic modifier and pluripotent factor PRMT7. Notably, 
both miR-221-3p and miR-221-5p can target the 3’ untranslated regions of the major pluripotent 
factors Oct4, Nanog and Sox2 to antagonize mouse ESC stemness while miR-221-5p additionally 
silences expression of its transcriptional repressor PRMT7. Transfection of miR-221-3p and miR-
221-5p mimics induced spontaneous differentiation of mouse ESCs. CRISPR-mediated miR-221 
deletion and anti-sense miR-221 inhibitors inhibited spontaneous differentiation of PRMT7-
depleted mouse ESCs. These results reveal that PRMT7-mediated repression of miR-221-3p and 
miR-221-5p is critical for maintaining mouse ESC stemness. Taken together, these two studies 
establish SETD5 and miR-221 as novel anti-stemness regulators that play a pro-differentiation 
role in ESC differentiation. 
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INTRODUCTION 
  
2 
 
1.1 GENERAL BACKGROUND OF EMBRYONIC STEM CELLS 
In 1954, Stevens et al. reported that the spontaneous testicular teratomas from an inbred 
strain of mice contained nervous tissues, cartilage, bone, muscle, fat and undifferentiated 
embryonic cells (1). Dr. Stevens further described that the undifferentiated embryonic cells are 
pluripotent and “appear to give rise to both rapidly differentiating cells and others which, like 
themselves, remain undifferentiated.” This was the first report of the pluripotent cells, which were 
later known as embryonic carcinoma cells due to the cells’ origin from carcinoma cells.  
The term of embryonic stem cells (ESCs) was coined by Dr. Gail Martin. In 1981, she and 
another group led by Dr. Martin Evans were first to derive mouse ESCs from mouse embryos. 
(2,3) These cells are pluripotent and can differentiate into a wide variety of cell types. Therefore, 
she gave the term of ESCs to denote their origin directly from embryos and to distinguish them 
from embryonic carcinoma cells. Nowadays, mouse or human ESCs can be derived from inner 
cell masses of blastocysts (4) and are defined by two main characteristics: 1) capability of long-
term self-renewal and 2) ability to form all three germ layers and to differentiate into all kinds of 
different cell types (pluripotency). (5) The stemness of ESCs is maintained by pluripotent 
transcription factors, including Oct4, Nanog, Sox2, and their regulatory network (6-11). These 
factors co-occupy and activate numerous genes that are important for maintaining ESC 
pluripotency (e.g., STAT3, Klf4 and c-Myc) while inhibiting lineage-specific genes to prevent ESC 
differentiation (e.g., Hox clusters, Pax6 and Meis1) (12,13). Oct4, Nanog and Sox2 can also bind 
to their own promoters and form positive feedback loops to auto-regulate their own expression 
(14).  
Under the right conditions, we can induce ESC differentiation into three different embryo 
germ layers: mesoderm, endoderm, and ectoderm (15). ESC differentiation requires rapid 
downregulation of pluripotent networks as well as upregulation of lineage-specific markers. The 
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downregulation of pluripotent factors depends on several different epigenetic mechanisms such 
as histone modification, DNA methylation and miRNA regulation (14). The in vitro differentiation 
of ESCs is an excellent model to mimic the early stage of embryo development at cellular level. 
Several technologies to manipulate genes (e.g., RNA interference and CRIPR/Cas9 gene editing) 
have become useful tools to study how developmental genes be regulated in ESC differentiation.  
 
1.2 GENERAL BACKGROUND OF EPIGENETICS 
All cell types that originate from the fertilized egg during development in principle share 
the same DNA sequence. However, various cell types have diverse phenotypes with different gene 
expression profiles. In addition, they may have different responses to same stimuli, and some 
genes are only transcribed and expressed under certain stimuli or environmental conditions. The 
mechanisms underlying this phenomenon are a fundamental question in the field of biology. In 
1942, Conrad Waddington first coined the word “epigenetics” as he proposed a concept to study 
the mechanisms of developmental processes between genotype and phenotype (16). He later 
defined epigenetics as “the branch of biology which studies the causal interactions between genes 
and their products, which bring the phenotype into being” (17). Now, with the advances in 
knowledge of this field, epigenetics is defined as “a stably heritable phenotype resulting from 
changes in a chromosome without alterations in the DNA sequence” (18). The detailed 
mechanism of epigenetics can be further characterized into several different categories, including 
the post-translational modifications of histones, DNA methylation, ATP-dependent chromatin 
remodeling, histone variants incorporation, and non-coding RNA pathways (19). 
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1.3 POST-TRANSLATIONAL MODIFICATIONS OF HISTONES 
Chromatin is a complex structure that is composed of DNA, proteins and RNA. 
Surprisingly, two-meter long DNA is packaged via chromatin in the nucleus (approximately 6 m 
in diameter) (20,21). The compact structure of chromatin is dynamically regulated and is 
important for gene regulation (22). Chromatin can be further characterized into euchromatin or 
heterochromatin. Chromatin is loosely packed in euchromatin regions. Therefore, transcription 
machinery can easily access DNA in euchromatin regions so that genes in the regions are actively 
transcribed (23). In contrast, heterochromatin is a tightly packed chromatin, and its compact 
structure prevents the access of transcription machinery while resulting in gene silencing (24).  
The nucleosome is the basic unit of chromatin and consists of a histone octamer wrapped 
around 147 base pairs of DNA. Histone proteins contain high amounts of basic amino acids (e.g., 
lysine and arginine) and therefore are positively charged. The positively charged histones play a 
pivotal role in controlling the structure of the chromatin and accessibility of DNA. Two H2A-
H2B dimers and one H3-H4 tetramer form the core histone octamer whereas histone H1 serves as 
a linker histone (25). The N-terminal tails of the histones are more flexible and are subjected to 
post-translational modifications, including methylation, phosphorylation, acetylation, ADP 
ribosylation, ubiquitylation, and sumoylation (26). These modifications can change the structure 
of the nucleosome through altering the charge on histones or serving as binding sites to recruit 
downstream proteins to modulate several biological processes, such as gene expression, DNA 
repair, and DNA replication (27).  
The histone code hypothesis proposes that the different combinations of histone 
modifications may have distinct readouts for gene regulation (28). The histone modifications are 
dynamically regulated by epigenetic modifiers. The enzymes that add the modifications to the 
histone are called “histone writers”; whereas, the enzymes that remove the modifications are 
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“histone erasers”. These epigenetic modifiers play important roles in regulating gene expression. 
Specific modifications can be recognized by proteins known as “histone readers”, which can 
further recruit transcription machinery or change chromatin conformation to activate or repress 
the expression of target genes. Emerging evidence shows that dysregulation of these epigenetic 
regulators may lead to several severe developmental diseases and cancer development (29).  
1.4 HISTONE METHYLATION 
Histone methylation is an important epigenetic modification that regulates gene 
expression and consequently affects numerous biological processes, such as embryonic 
development, cell differentiation, and cancer development (30). Histones can mainly be 
methylated on lysine or arginine residues. There are three different states of methylation on lysine 
-amine group - i.e., mono-methylation (me1), di-methylation (me2) and tri-methylation (me3) 
(31) (Figure 1A). For arginine methylation, there are also three different types of methylation: 
mono-methylation (me1), asymmetric di-methylation (me2a) and symmetric di-methylation 
(me2s) (32) (Figure 1B). The positive charge on histone lysine and arginine residues are important 
for DNA packaging and chromatin structure. Histone acetylation and phosphorylation change the 
net charge on histones, thereby altering the chromatin accessibility to several cellular machineries 
such as transcription and DNA repair (33,34). In contrast, histone methylation has a minimal effect 
on the overall charge of lysine or arginine residues of histones, but creates a binding motif to 
recruit downstream effector proteins to achieve specific biological outcomes (35). These 
downstream effector proteins contain methylation binding domains, including PHD finger, 
chormodomain , WD40 domain, tudor domain and PWWP domains (36). For example, TATA 
box-binding protein associated factor 3 (TAF3) contains a PHD finger domain which can strongly 
bind to tri-methylated histone H3 lysine 4 (H3K4me3) at the promoters and recruit the TFIID 
complex to the promoters for transcription initiation (37,38). 
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Figure 1  Lysine and arginine methylation  
(A) Histone methyltransferases methylate the -amine group of lysine into mono-methylation, di-
methylation and tri-methylation. (B) Arginine residues can be methylated by PRMTs into mono-
methylation, asymmetric di-methylation and symmetric di-methylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
1.5 SET DOMAIN-CONTAINING HISTONE METHYLTRANSFERASES AND 
DISEASES 
Histone methylation is established by histone methyltransferases (HMTase) which can be 
classified into three different families, including SET domain-containing methyltransferase, 
seven--strand methyltransferase, and protein arginine methyltransferase (PRMT). The SET 
domain-containing proteins can transfer methyl groups from S-Adenosyl methionine (SAM) to 
lysine residues of target proteins through their catalytic SET domain (39). The seven--strand 
methyltransferase family can methylate a variety of substrates, including lipids, nucleic acids and 
proteins. Until now, Dot/DOTlL was the only histone-specific methyltransferase that belonged to 
this group (40). The third group of HMTases are protein arginine methyltransferases which can 
also use SAM as a cofactor and transfer methyl groups to the arginine residues on histones (32).  
The SET domain-containing proteins are major histone lysine methyltransferases and are 
highly conserved from yeast to humans. So far, 51 SET domain-containing proteins have been 
identified according to the SMART database. SET is an acronym comprising three different 
Drosophila melanogaster proteins: Su(var)3-9, Enhancer-of-zest and Trithorax, which all contain 
approximately 130-amino acid long conserved sequences and possess HMTase activity (41,42). 
According to sequence alignment, two conserved sequence motifs, ELxF/YDY and NHS/CxxPN 
(x being any amino acid) have been identified in the SET domain. It has been shown that the 
NHS/CxxPN motifs play important roles in the binding of cofactor SAM (43-45). In general, the 
structure of the SET domain can be divided into three parts: core SET, pre-SET (N-SET, n-
terminal), and post-SET (C-SET, c-terminal). The pre-SET and post-SET provide scaffold 
structures to complement the core SET for specific substrate recognition and cofactor binding. 
Based on crystal structure analysis, the substrate peptide and the cofactor SAM bind to different 
sides of the SET domain and meet at the active site located at the core SET (46). 
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Numerous reports have shown that mutations on HMTases are associated with severe 
developmental disorder and tumorigenesis. For example, Mixed lineage leukemia 1 (MLL1) is a 
histone H3 lysine 4 (H3K4) methyltransferase which locates on chromosome 11q23. 
Chromosome translocations on the MLL1 gene have been linked to several types of leukemia, 
including MLL, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (47,48). 
It has been shown that the translocation leads to the N-terminal of MLL1 to fuse with other 
proteins (e.g. ENL, ELL and AF9) and creates a new chimeric protein (e.g. MLL-ENL, MLL-
ELL and MLL-AF9) (49). Because the catalytic SET domain of MLL1 is at the C-terminal end, 
the MLL1 translocation results in the loss of the SET domain as well as methyltransferase activity. 
Moreover, several MLL1 translocation partners are members of the super elongation complex 
(SEC), including ENL, ELL and AF9.  Therefore, the new chimeric protein may lead to 
dysregulation of MLL target genes and transcription elongation, which play an important role in 
the pathogenesis of leukemia (50,51). Another example is MLL4 (KMT2D/MLL2/ALR), an 
H3K4 methyltransferase, which acts as a key regulator by establishing the enhancer mark 
H3K4me1 (52). Several different mutations on MLL4 have been found in patients with Kabuki 
syndrome, which is a congenital disorder characterized by mental retardation, distinctive facial 
characteristics, congenital heart disease, and skeletal abnormalities (53,54). Moreover, several 
studies also showed that the loss-of-function mutations on MLL4 often occur in childhood 
medulloblastoma (55,56). These reports further support the importance of SET domain-containing 
HMTases in regulating development and tumorigenesis. Therefore, it is critical to further 
understand the detailed molecular mechanisms and biological functions of these SET domain-
containing HMTases. 
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1.6 HISTONE LYSINE METHYLATION AS A SIGNATURE FOR GENE REGULATION 
During past several years, histone modifications and their functions have been extensively 
studied. There are six major lysine methylation sites on histones, including H3K4, H3K9, H3K27, 
H3K36, H3K79, and H4K20. Functional studies have revealed the important roles of these histone 
lysine methylation marks in gene regulation. In general, methylation on H3K4, H3K36, and 
H3K79 are associated with gene activation while H3K9, H3K27, and H4K20 are associated with 
gene repression (57-59) (Figure 2A). Trimethyl H3K4 decorates transcriptional start sites (TSS), 
and its levels are positively correlated with transcription frequency (60). Trimethyl H3K36 is 
enriched near the 3’ end of active gene and has been implicated in transcription elongation (61). 
H3K79 methylation is strongly correlated with gene activity and is localized at active genes (62). 
In contrast, H3K9 methylation has been shown to regulate heterochromatin formation (e.g. X 
inactivation) and gene silencing (63). H3K27 methylation serves as a binding site for the 
polycomb repressive complex (PRC), which represses gene expression. H4K20 methylation 
prevents the formation of the active mark H4K16 acetylation (H4K16Ac), which leads to RNA 
PolII promoter-proximal pausing and gene repression (64). 
With the development of chromatin immunoprecipitation (ChIP) followed by genome-
wide sequencing (ChIP-seq), the genome-wide distribution of histone modifications has been 
determined (65). Computational analysis has shown that specific histone modifications may 
correlate with different functional elements in the genome (also known as chromatin states, e.g. 
promoters, enhancers, gene bodies and repressed genes) (66). For example, the transcriptional 
start sites (TSS) of active promoters are generally marked by H3K4 trimethylation (H3K4me3) 
(67), while H3K4 monomethylation (H3K4me1) and acetylation on H3K27 generally marks 
active enhancers (68,69). These histone modifications often serve as binding sites to recruit 
downstream effector proteins. For example, the chromatin remodelers CHD1 and BPTF are 
11 
 
recruited to the TSS through binding to H3K4me3 to relax chromatin structure and allow the 
access of transcriptional machinery (70,71). In addition, the TFIID complex component TAF3 can 
strongly interact with H3K4me3 and recruit the pre-initiation complex (PIC) to the TSS for 
transcription activation (38). 
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Figure 2.  Six major histone lysine methylation sites 
H3K4, H3K9, H3K27, H3K36, H3K79, and H4K20 are major histone lysine methylation sites 
that play important roles in gene regulation. Methylation on H3K4, H3K36, and H3K79 is 
associated with gene activation. Methylation on H3K9, H3K27, and H4K20 is associated with 
gene repression. 
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2.1 INTRODUCTION 
2.1.1 SET Domain-containing protein 5 (SETD5) 
SET domain-containing 5 (SETD5)/KIAA1757 was originally identified from a human 
cDNA sequencing project and was shown to be ubiquitously expressed across human tissues with 
predominantly high levels in brain tissue (72). At least two SETD5 isoforms have been identified 
in human and mouse. SETD5 isoform 1 (canonical sequence) consists of 23 exons that encode a 
protein of 1442 amino acids with an estimated molecular weight of 163 kDa. SETD5 isoform 2 
also consists of 23 exons but encodes a longer protein product with 1661 amino acids. This longer 
isoform has an alternative 3’ splicing site on exon 4 which generates a 19-amino acid-insertion at 
codon 59 (A ADHNYGAPPPPTPPASPPVQ) (Figure 3A). SETD5 contains one SET domain 
near its N-terminal and is considered a putative HMTase (Figure 3A). However, the enzymatic 
activity and functions of SETD5 have not been well characterized.  
Based on phylogenetic analysis and sequence alignment, SETD5 and another SET 
domain-containing protein, MLL5 (KMT2E), are paralogs with similar domain architecture and 
have highly conserved SET domains (73) (Figure 3A and 3B). MLL5 was originally identified 
as a SET domain-containing tumor suppressor in myeloid leukemia and therefore was categorized 
into the MLL family, which includes MLL1, MLL2, MLL3, and MLL4 (74). However, a recent 
report by Mas-y-Mas et al. suggested that MLL5 is not a member of the MLL family but belongs 
in its own family with SETD5 since the SET domain of MLL5 is distinct from other MLL family 
proteins (75). Knockout mice of Mll5 showed partial lethality and multiple hematopoietic defects, 
suggesting the functional importance of MLL5 in development (76). Several groups have shown 
that MLL5 does not have intrinsic HMT activity but can indirectly regulate H3K4 methylation 
status through inhibiting the H3K4 demethylase LSD1 (76,77). Moreover, Mas-y-Mas et al. 
showed that the SET domain of MLL5 does not have a conserved NHS/CxxPN motif (NH is 
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replaced by RR) and may not bind SAM. In this study, crystal structure analysis demonstrated 
that the SET domain of MLL5 contains a large loop structure to prevent the binding of histone 
peptides (75) (Figure 3B). Based on the fact that the SET domains of MLL5 and SETD5 are 
highly conserved, it implies that SETD5 may also lack intrinsic HMT activity.  
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Figure 3.  SETD5 is a putative histone methyltransferase which has been linked to 3p25 
microdeletion syndrome 
(A) Diagrammatic representation of mouse MLL5, SETD5 isoform 1, and SETD5 isoform 2. 
PHD, plant homeodomain. SET, Su(var)3-9, Enhancer-of-zest and Trithorax domain. SETD5 
isoform 2 contains a 19 amino acid insertion at the N-terminal of SETD5. (B) Sequence alignment 
of the SET domain of SETD5 and MLL5 with other SET domain-containing histone 
methyltransferases, including MLL1, MLL2, MLL3, MLL4, SET1A, SET1B, and EZH2. The 
conserved ELxF/YDY and NHS/CxxPN motifs are highlighted in grey. The SET domain of 
SETD5 and MLL5 do not have conserved NHS/CxxPN motifs, as the aspargine (N) and histidine 
(H) are replaced by two arginine residues (RR) (highlighted in yellow).  
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2.1.2 Rationale and hypothesis 
As mentioned previously, epigenetic regulation is essential in ESC differentiation and 
embryonic development. In our effort to identify epigenetic regulators that are critical for ESC 
differentiation, we examined the expression profile of 36 histone methylation modifiers to 
determine which histone methylation modifiers are up-regulated during ESC differentiation. We 
found that expression levels of SETD5 increased across stages of RA-induced mouse ESC 
differentiation (Figure 4). SETD5 is a putative histone methyltransferase, although its function 
and enzymatic activity remain elusive. Interestingly, Osipovich et al. showed that Setd5-null mice 
were embryonic lethal (78). Moreover, several clinical reports indicated that de novo loss-of-
function mutations in SETD5 can cause intellectual disability and autism, further pointing to an 
important role for SETD5 in ESC differentiation, embryogenesis, and development (79-82). 
Therefore, we hypothesized that SETD5 is required for mouse ESC differentiation. In this study, 
we utilized biochemical and molecular biological approaches to determine SETD5’s catalytic 
activity and its function in mouse ESC differentiation. 
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Figure 4.  The expression level of 36 epigenetic regulators in different stages of RA-induced 
mouse ESC differentiation 
Comparison of relative mRNA level of 36 epigenetic regulators in different stages of RA-induced 
mouse ESC differentiation. EB, 5 days after embryoid body generation; RA, 5 days after retinoic 
acid treatment. 
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2.2 MATERIALS AND METHODS 
2.2.1 Antibodies, plasmids and other reagents 
Anti-HA antibodies were purchased from Abcam (ChIP grade, ab9110) and Biolegend 
(#901501). Anti-HCF1 (A301-399A), was from Bethyl Labortories. Anti-Oct4 (#2840 antibody 
was from Cell Signaling. Anti-β-actin antibody (A5441) and anti-FLAG (F1804) was from 
Sigma-Aldrich. Anti-H3 antibody (ab1791) was from Abcam. Anti-SETD5 antibody was custom 
generated by Thermo Fisher. FLAG-tagged expression vector pFlagCMV2 and GST-tagged 
bacterial expression vector pGEX6P1 was obtained as previously described (83). Baculoviral 
expression vector pFastBac-HTa was obtained as previously described (84). 
Lentiviral expression vector pCDH-EF1-IRES-Neo was a gift from Dr. Mien-Chie Hung. 
pGEX6P1-SET7 was kindly provided by Dr. Xiaobing Shi. Oligonucleotides used for cloning, 
site-directed mutagenesis, RT-PCR, ChIP-PCR and CRISPR-Cas9 are listed in Table 1. 
Table 1 SETD5 Oligonucleotide sequences. 
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2.2.2 Mouse ESC culture and AP staining 
V6.5 mouse ESC were cultured on gelatin-coated plates in complete knockout Dulbecco 
modified eagle’s medium (Life technology) supplemented with 20% ES grade FBS (GenDEPOT), 
2 mM L-glutamine, 50 g/ml penicillin and 50 g/ml streptomycin (Life technologies), 0.1 mM 
-mercaptomethanol, 0.1 mM nonessential amino acid (NEAA), and 1,000 U/ml leukemia 
inhibitory factor (LIF, homemade). mESC were trypsinized and split every 3 days while medium 
was changed daily. Alkaline phosphatase is a universal pluripotent marker for all types of 
pluripotent stem cells. Red-Color AP Staining kit was purchased from System Biosciences and 
mouse ESC were stained according to manufacturer’s instruction. 
 
2.2.3 Retinoic acid (RA)-induced differentiation of mouse ESCs 
In order to induce differentiation, we first generate embryoid body (EB) from V6.5 mouse 
ESC. The generation of EB allow ESC to grow under three dimensional condition which mimic 
the real embryogenesis. Briefly, V6.5 mouse ESC were trypsinized and suspended in 10 cm low 
attachment petri dish (Fisher) with ESC media without adding LIF. Under this condition, the 
suspended mouse ESC will not attach to culture dish and form round-shaped cell aggregates called 
as EB. After 5 days of incubation, the suspended EB were transferred to gelatin-coated tissue 
culture dish allowing the attachment of EB and 0.5 M RA was then added to induce further 
differentiation. After 5 days of RA treatment, the differentiated cells spread out from the attached 
cell aggregates and were harvested for further analysis (Figure 5). 
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Figure 5.  Retinoic acid (RA)-induced Differentiation of Mouse ESCs 
Schematic diagram representation for the procedure of retinoic acid-induced mouse ESCs 
differentiation. 
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2.2.4 RNA interference 
Mouse shSETD5 (shSETD5-1, TRCN0000098701; shSETD5-5, TRCN0000098700) and 
mouse shHCF1 (shHCF1-1 TRCN0000235784; shHCF1-5, TRCN0000086292) in the 
puromycin-resistant PLKO.1 vector were purchased from Sigma-Aldrich. The shRNA plasmids 
(30 µg) were transfected into mouse ESCs (5 X 105 cells in 0.8 mL) by using Gene Pulser Xcell 
Electroporation System (500 µF, 250 volts; BioRad) according to the manufacturer’s protocol and 
were plated on a 6 cm dish. The cells were treated with puromycin (1.0 µg/ml) 48 h later to obtain 
stable clones. 
 
2.2.5 Western blot analysis 
Mouse ESCs were lysed by mammalian lysis buffer (20 mM Tris-HCl, 137 mM NaCl, 1.5 
mM MgCl2, 1mM EDTA, 10% glycerol, 1% TritonX-100, 0.2 mM PMSF) to obtain total cell 
lysates. Protein concentration was determined by Bradford Protein Assay (BioRad). 20 g of total 
protein were subjected to standard western blot analysis. Antibodies against HA, SETD5, OCT4, 
NANOG, NESTIN and -ACTIN are used for immunoblotting. 
 
2.2.6 Quantitative PCR for mRNA expression 
Total RNAs were isolated by using Quick-RNA MiniPrep kit (Zymo Research). To detect 
relative mRNA level, cDNA was synthesized by using iScript cDNA Synthesis Kit (BioRad) 
according to manufacturer’s instruction. Quantitative PCR was performed by using CFX384 real-
time PCR detection system (BioRad) and GAPDH level were used as internal control.  
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2.2.7 Rescue experiments by ectopic expression of SETD5 
To ectopic express SETD5 in V6.5 mouse ESC, FLAG-tagged full length mouse SETD5 
cDNA was cloned into pCDH-EF1-IRES-Neo vector to obtain FLAG-SETD5 expression 
construct (pCDH-EF1-FLAG-SETD5-IRES-Neo). Next, pCDH-EF1-IRES-Neo empty vector 
and pCDH-EF1-FLAG-SETD5-IRES-Neo were transfected into shSETD5-5-treated cells by 
using Lipofectamine 3000 (Life technology) according to manufacturer’s protocol. 48 h after 
transfection, cells were treated with puromycin (InvivoGen, 1.0 µg/ml) and geniticin (Life 
technology, 500 µg/ml) for 14 days to obtain stable clones. To perform rescue experiment, shLuc-
treated cells, shSETD5-5-treated cells, and two geniticin-resistant cells (shSETD5-5+Vector and 
shSETD5-5+FLAG-SETD5) were subjected to RA-induced ESC differentiation assay for further 
analysis. 
 
2.2.8 CRISPR/Cas9 gene editing 
pSpCas9n(BB)-2A-GFP (PX461) plasmid with nCas9 (D10A nickase mutant) were 
obtained from Addgene. To generate Setd5-2XHA knock-in V6.5 mouse ESC, two guide RNA 
(sgRNA) sequences around the stop codon (inside exon 22) of SETD5 (F1: 
TTGACTCCTGACCCTTGCAG; F2: CAGGACTTTCCTAGGGCTTC) were cloned separately 
into pSpCas9n(BB)-2A-GFP. Single-stranded donor oligonucleotides (ssODN) repair template 
which contains 2XHA sequences was synthesized by IDT (ssODN seqence: 
GGGGGTGTACACCAGTACCGACTCCAGCCACTGCAAGGGTCAGGAGTCAAGACTCA
GACAGGACTTTCCGGCGGAGGTTACCCATACGATGTTCCAGATTACGCTGGCTATCCA
TATGACGTTCCAGATTACGCTGTCGACTAGGGCTTCTGGATATGGGCAAACTGAACTT
AATGAGCCCATAGCTGCTTCCTTCC). sgRNA-containing plasmids and ssODN repair 
template were then co-transfected into V6.5 mouse ESCs by using Lipofectamine 3000 according 
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to manufacturer’s protocol. After 48 h of incubation, mouse ESCs were trypsinized and sorted by 
GFP signals. GFP-positive mouse ESCs were plated into 96 well plate (one cell per well) to obtain 
single colony for further selection. 
 
2.2.9 Chromatin Immunoprecipitation (ChIP) assay 
ChIP assay was performed as previously described with small modification (85). Mouse 
ESCs were first fixed by 1% formaldehyde. Cell pellets were then lysed with ChIP lysis buffer 
and sonicated by using Bioruptor (Diagenode) for 5 min (30 sec on and 30 sec off for 5 cycles) to 
shear the DNA. The DNA was further digested by adding 10U of Benzonase (Sigma) and 
incubated for 15 min on ice to obtain a smear of DNA from 200 bp to 500 bp. Antibodies were 
added and incubate for overnight at 4 °C. Pre-blocked protein A beads were added and incubated 
for another 1-2 hr to capture protein-DNA complex. The beads were then washed once with 
following buffer: low-salt buffer, high-salt buffer, LiCl buffer and TE buffer. ChIP DNA were 
then eluted by ChIP elution buffer (1% SDS and 0.1M NaHCO3). The eluate were reverse-
crosslinked and ChIP DNA were purify by phenol/chloroform extraction method. 
 
2.2.10 Immunoprecipitation assay 
Immunoprecipitation assay was performed as previously described (83). To test the 
interaction between SETD5 and RAR-, FLAG-RAR- was transiently expressed in HEK 293T 
cells by Lipofectamine 2000 (Life technologies) according to manufacturer’s protocol. 48 h after 
transfection, DMSO or 10 M retinoic acid was added to cells and incubated for another 1 h. Total 
cell lysates were then harvested by adding mammalian lysis buffer and Anti-FLAG M2 affinity 
gel (Sigma) was added and incubated in 4 ⁰C for 5 h to perform FLAG-immunoprecipitation. The 
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affinity gel was washed with BC500 (20 mM Tris-HCl, 500 mM KCl, 1.5 mM MgCl2, 0.2 mM 
EDTA, 10% glycerol, 0.2mM PMSF at pH 8.0).and eluted by by using 0.4 g/mL of FLAG 
peptides in HMT buffer (50 mM Tris-HCl, 100 mM KCl, 5 mM MgCl2, 4 mM DTT and 10% 
glycerol at pH 8.5). The eluates were subjected to SDS-PAGE followed by western blot analysis 
and stored for further analysis. 
To verify the endogenous interaction between SETD5 and HCF1 in mouse ESC, total cell 
lysates from wild-type and Setd5-2XHA knock-in mouse ESCs were harvested to perform HA-IP. 
Briefly, Anti-HA agarose (Pierce) was added to total cell lysates and incubated overnight. The 
agarose gel was washed with mammalian lsysis buffer and eluted by using 1 g/mL of HA 
peptides (Sigma). The eluates were subjected to SDS-PAGE followed by western blot analysis. 
 
2.2.11 Recombinant protein purification 
To obtain full length SETD5 recombinant protein, FLAG-tagged mouse SETD5 cDNA 
was cloned into pFastBac-HTa vector. The construct was transformed into DH10Bac competent 
cells (Invitrogen) to generate recombinant Bacmid. Recombinant Bacmid DNA was then 
transfected into Sf9 insect cells by using Cellfectin (Invitrogen) to generate recombinant 
baculoviruses. The fell-length FLAG-SETD5 recombinant protein was expressed by infecting 
Sf21 insect cells with recombinant baculoviruses. 72 h after infection, the Sf21 cells was harvested 
and FLAG-immunoprecipitation was performed to obtain full length FLAG-SETD5 recombinant 
protein. 
To obtain GST-tagged SETD5-SET domain recombinant protein, SETD5 N-terminal 
fragment (1-500 a.a.; SETD5 SET domain: 291 ~415 a.a.) was cloned into pGEX-6P-1 GST 
expression vector (pGEX-6P-1-SETD5-SET). GST-SETD7 expression plasmid (pGEX-6P-1-
SETD7) was kindly provided by Dr. Xiaobing Shi. The plasmids were transformed into BL21 
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competent cells and recombinant protein expression was inducted by adding Isopropyl β-D-1-
thiogalactopyranoside (IPTG) at 16 °C. 20 h after induction, the bacteria was harvested and lysed 
by mammalian lysis buffer. Cell lysates were then incubated with Glutathione Sepharose 4B (GE 
Healthcare) for overnight to perform GST pull-down assay. GST fusion protein were purified and 
eluted by elution buffer (10 mM glutathione, 100 mM Tris HCl [pH 8.0]).  
 
2.2.12 Affinity purification of SETD5 complex 
Mouse SETD5 cDNA was cloned into pFlagCMV2 (FLAG-SETD5) and SET domain 
deletion mutant in the same expression vector (FLAG-SETD5-SET) was generated by using 
OuickChange Site-Directed Mutagenesis Kit mutagenesis assay (Agilent). The plasmids were 
transiently expressed in HEK 293T cells and nuclear extracts were isolated 48 h after transfection. 
SETD5 complex were purified by using FLAG-immunoprecipitation. FLAG-IP eluates were then 
subjected to silver staining, in vitro histone methyltransferase (HMT) assay and liquid 
chromatography-tandem mass spectrometry. 
 
2.2.13 In vitro histone methyltransferase (HMT) assay 
Recombinant protein and FLAG-IP eluates were incubated with 1 g of recombinant H2A, 
H2B, H3, H4 (New England BioLabs) or recombinant nucleosomes. [3H]-labeled S-adenosyl-L-
methionine ([3H]-SAM) was added to the reaction mix to serve as methyl donor. All reaction were 
performed in HMT buffer (50 mM Tris-HCL, 100 mM KCL, 5 mM MgCl2, 4 mM DTT and 10% 
glycerol at pH 8.5) and incubated for 16 h in 30 ⁰C. The reaction was stopped by adding SDS 
sample buffer and was subjected to SDS-PAGE. The HMT signal was then detected by 
autoradiography. 
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2.2.14 Radioactive S-adenosyl-L-methionine (SAM) binding assay 
1 g of GST fusion protein (GST, GST-SETD7 and GST-SETD5-SET) were incubated 
with 2.5 Ci of [3H]-labeled S-adenosyl-L-methionine ([3H]-SAM) in SAM binding buffer (100 
mM Tris HCl [pH 8.0]) for 1 h at 30 ⁰C. Binding mixtures were then pull-down by Glutathione 
Sepharose 4B (GE Healthcare) and unbound [3H]-SAM was removed by washing 3 times with 
binding buffer. GST fusion protein were eluted by elution buffer (10 mM glutathione, 100 mM 
Tris HCl [pH 8.0]). The bound [3H]-SAM was detected by Liquid Scintillation Spectrometry (LS 
6000 Scintillation Counter, Beckman). 
2.2.15 Statistical analysis 
The statistical significance between the two groups was analyzed by student’s t-test using 
Prism software (GraphPad Software Inc.). Data are presented as the mean ± standard deviation 
(SD) of at least three independent experiments. P < 0.05 (*), P < 0.01 (**), and P < 0.001(***) 
indicate statistically significant changes. 
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2.3 RESULTS 
2.3.1 SETD5 is required for proper mouse ESC differentiation. 
In order to determine the role of SETD5 in ESC differentiation, we employed RA-induced 
differentiation of mouse ESCs, as this is a well-established in vitro differentiation model system 
(85,86). We first examined the expression level of SETD5 across different stages of RA-induced 
mouse ESC differentiation. Quantitative RT-PCR results showed that Setd5 mRNA levels 
gradually increased during RA-induced mouse ESC differentiation (Figure 6A). Consistent with 
this, Western blot analysis showed that SETD5 protein levels also increased (Figure 6B). To 
assess the role of SETD5 in RA-induced mouse ESC differentiation, we depleted SETD5 in V6.5 
mouse ESCs by using two independent shRNAs against SETD5 (shSETD5-1 and shSETD5-5). 
SETD5 knockdown was confirmed by quantitative RT-PCR and Western blot analysis (Figure 
6C and 6D). SETD5 knockdown appeared not to affect the pluripotency of mouse ESCs because 
SETD5-depleted cells were morphologically normal compared to the control, as they formed 
round-shaped colonies after several passages (Figure 6E). Next, we compared RA-induced mouse 
ESC differentiation between shLuc-treated and SETD5-depleted cells. During the generation of 
EB, SETD5 depletion had no obvious effect on the size and shape of EBs (Figure 6E).  After RA 
treatment, round-shaped colonies of the shLuc-treated cells spread out and negatively stained for 
alkaline phosphatase (AP), a pluripotent marker. In contrast, as most SETD5-depleted ESCs still 
formed round-shaped colonies and stained positively for AP, SETD5 knockdown impeded RA-
induced differentiation of mouse ESCs (Figure 6E). These results indicate that SETD5 is essential 
for mouse ESC differentiation. 
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Figure 6.  Setd5 is required for RA-induced differentiation of mouse ESCs.  
(A) Comparison of relative mRNA level of SETD5 in different stage of RA-induced mouse ESC 
differentiation. EB, 5 days after embryoid body generation; RA, 5 days after retinoic acid 
treatment. (B) Western blot analysis of SETD5 and -actin (loading control) protein levels in 
different stages of RA-induced mouse ESC differentiation. (C) Analysis of relative mRNA 
expression levels between shLuc-treated and two SETD5-depleted (shSETD5-1 and shSETD5-5) 
mouse ESCs. (D) Western blot analysis of SETD5 and -actin (loading control) protein levels 
between shLuc-treated and two SETD5-depleted (shSETD5-1 and shSETD5-5) mouse ESCs. (E) 
Microscopic and AP staining images of shLuc-treated and two SETD5-depleted (shSETD5-1 and 
shSETD5-5) mouse ESCs in different stages of RA-induced mouse ESC differentiation. AP 
staining was performed 5 days after retinoic acid treatment. Data are presented as the mean ± SD 
of three independent experiments. P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***). 
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2.3.2 SETD5 activates the expression of differentiation-specific genes and the neuron-
related genes. 
The differentiation process of mouse ESCs requires rapid down-regulation of pluripotent 
factors (e.g. Oct4 and Nanog) and induction of lineage-specific genes to further differentiate into 
the precursors of different germ layers (14). The treatment of RA induces the neuronal lineage 
commitment of mouse ESC, which then differentiates into the ectodermal precursor cells (87). To 
understand how SETD5 regulates mouse ESC differentiation, we examined the effect of SETD5 
depletion on the expression level of several pluripotent factors and neuronal lineage-specific 
markers during RA-induced differentiation of mouse ESCs. Quantitative RT-PCR results showed 
the mRNA levels of pluripotent factors Oct4 and Nanog were less reduced in SETD5-depleted 
cells than in shLuc-treated cells after RA treatment (Figure 7A). These results are consistent with 
the above results that SETD5-depleted cells were positively stained with AP after RA treatment. 
Moreover, RA-induced activation of the differentiation-specific genes (Hoxa1 and Hoxa2) and 
the neuron-related genes (Nestin and Pax6) was also inhibited by depletion of SETD5 (Figure 
7A). Together, these data suggest that SETD5 depletion inhibited RA-induced differentiation of 
mouse ESCs. 
To confirm the specificity of shSETD5 and the role of SETD5 in mouse ESC 
differentiation, we performed a rescue experiment by stably expressing mouse SETD5 in stably 
SETD5-depleted cells. We first cloned FLAG-tagged full length mouse SETD5 into a pCDH-
EF1-IRES-Neo vector to obtain a FLAG-SETD5 expression construct (pCDH-EF1-FLAG-
SETD5-IRES-Neo). Next, we transfected empty vector or pCDH-EF1-FLAG-SETD5-IRES-Neo 
into stably SETD5-depleted cells and selected with geniticin to obtain geniticin-resistant stable 
clones. For stably SETD5-depleted cells, we chose shSETD5-5-containing stable cells to perform 
a rescue experiment, because shSETD5-5 is predicted to target the 3’UTR of mouse Setd5 and 
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thus may not have an effect on SETD5 expression. The stable expression of SETD5 was 
confirmed by anti-FLAG western blot analysis (Figure 7B). We compared RA-induced 
differentiation of the following 4 groups of ESC clones: (1) shLuc, (2) shSETD5-5, (3) shSETD5-
5+Vector, and (4) shSETD5-5+FLAG-SETD5. 
After RA treatment, the shSETD5-5+Vector group had an impaired differentiation 
morphology and was positively stained with AP. In contrast, the shSETD5-5+FLAG-SETD5 
group showed almost normal differentiation morphologies similar to those of the shLuc group and 
were negatively stained with AP (Figure 7C). Consistent with phenotypic observation and AP 
staining, quantitative RT-PCR results showed that RA-induced expression levels of 
differentiation-specific genes (Hoxa1 and Hoxa2) and the neuron-related genes (Nestin and Pax6) 
in the shSETD5-5+FLAG-SETD5 group were highly increased as compared to those in the 
shSETD5-5+Vector group while being similar to those in the shLuc group (Figure 7D). These 
results showed that the impaired RA-induced differentiation of SETD5-depleted cells can be 
rescued largely by SETD5 re-expression, confirming an essential role for SETD5 in proper mouse 
ESC differentiation. 
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Figure 7. Setd5 is necessary for RA-induced expression of differentiation-specific genes 
(Hoxa1 and Hoxa2) and neuron-relevant genes (Nestin and Pax6). 
(A) Analysis of relative mRNA level of Oct4, Nanog, Hoxa1, Hoxa2, Nestin and Pax6 between 
shLuc-treated and two SETD5-depleted (shSETD5-1 and shSETD5-5) mouse ESCs in different 
stage of RA-induced mouse ESC differentiation. (B) Ectopic expression of SETD5 for rescue 
experiment. SETD5-depleted cells (shSETD5-5) were transfected with pCDH-EF1-IRES-Neo 
vector (shSETD5-5+Vector) or pCDH-EF1-FLAG-SETD5-IRES-Neo (shSETD5-5+FLAG-
SETD5) and selected with geniticin to obtain geniticin-resistant stable clones. The protein level 
of SETD5, FLAG and -actin (loading control) were examined by western blot analysis. (C) 
Microscopic and AP staining images between shLuc-treated, SETD5-depleted (shSETD5-5), 
shSETD5-5+Vector and shSETD5-5+FLAG-SETD5 cells in different stage of RA-induced mouse 
ESC differentiation. AP staining was performed 5 days after retinoic acid treatment. (D) Analysis 
of relative mRNA level of Hoxa1, Hoxa2, Nestin and Pax6 between shLuc-treated, SETD5-
depleted (shSETD5-5), shSETD5-5+Vector and shSETD5-5+FLAG-SETD5 cells in different 
stage of RA-induced mouse ESC differentiation. Data are presented as the mean ± SD of three 
independent experiments. P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***). 
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2.3.3 Generation of Setd5-2XHA knock-in mouse ESCs by CRISPR-Cas9 system 
To assess whether SETD5 directly regulates Hoxa1-2, Nestin, and Pax6 genes, we 
performed quantitative chromatin immunoprecipitation (qChIP) for SETD5 using commercially 
available SETD5 antibodies. However, we failed to obtain successful ChIP results in these genes, 
perhaps because of the poor quality of commercially available SETD5 antibodies. In the end, we 
decided to insert a tandem HA tag in the c-terminal end of Setd5 gene (Setd5-2xHA) in V6.5 
mouse ESCs, because an HA tag would allow us to use anti-HA antibody to perform qChIP assay 
for SETD5.  
For the knock-in strategy, we took advantage of the recently developed CRISPR-Cas9 
gene editing technology. Cas9 is an RNA-guided DNA endonuclease that can create specific DNA 
double strand breaks at target sites in living cells. We cloned two 20 bp-long single-guide RNAs 
(sgRNA) sequences into a Cas9 D10A nickase-GFP expression plasmid to target exon 22 of the 
mouse Setd5 gene and to generate a DNA double strand break near the stop codon (Figure 8A). 
We also designed a repair template containing homologous arms flanking the insertion sequence 
so that the desired insertion at the target locus occurs in cells via homology-directed repair (HDR)  
(88). For the insertion sequence in the repair template, we placed the tandem HA tag at the C-
terminal end of SETD5 (before the stop codon) to avoid interfering with endogenous SETD5 
enzymatic activity because the SET domain of SETD5 is close to N-terminal (Figure 8D).  
Next, we transfected sgRNA-Cas9-GFP plasmids along with single-stranded donor 
oligonucleotides (ssODN) as a repair template which contains 2XHA sequences into V6.5 mouse 
ESCs and performed GFP-based cell sorting to obtain Cas9-expressing cells (Figure 8A). Of the 
84 clones screened, we were able to obtain a homozygous insertion clone (clone #17) which was 
confirmed by genomic PCR followed by DNA sequencing (Figure 8B and 8C). The SETD5-
2XHA clone #17 was morphologically normal, because it formed round-shaped colonies and was 
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positively stained by AP (Figure 8E). The expression of SETD5-2XHA was further confirmed by 
immunoblotting and immunoprecipitation (Figure 8F and 8G). It should be noted that the 
insertion of 2XHA tag did not affect endogenous SETD5 protein level (Figure 8F).  
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Figure 8. Generation of Setd5-2XHA knock-in mouse ESCs by CRISPR-Cas9 system 
(A) Schematic representation the design of CRISPR/Cas9 targeting sites for generating Setd5-
2XHA knock-in V6.5 mouse ESCs. Two guide RNAs (sgRNAs) sequences in the last exon (exon 
22) of Setd5 are labelled with underlines. The PAM sequences are labelled in red and the stop 
codon is labelled in blue. (B) Sequencing results and chromatograms for Setd5-2X-HA clone #17.  
(C)  PCR using primers flanking the last exon of Setd5 in wild-type and Setd5-2XHA knock-in 
V6.5 mouse ESCs. The wild-type PCR band is predicted to be 500 bp. Setd5-2X-HA clone #17 
showed homozygous knock-in. (D) Schematic representation the protein product of Setd5-2X-HA 
knock-in. (E) Microscopic images of wild-type and Setd5-2X-HA clone #17 mouse ESCs. (F) 
Western blot analysis of HA, SETD5 and -actin protein levels between wild-type and Setd5-2X-
HA knock-in mouse ESCs. (G) Total cell lysate from Setd5-2X-HA knock-in mouse ESCs was 
immunoprecipitated by using IgG or HA antibody (Abcam), followed by western blot analysis 
with HA antibody (Biolegend). 
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2.3.4 Setd5 depletion also inhibits RA-induced differentiation of Setd5-2XHA knock-in 
mouse ESCs 
To assess whether cellular characteristics of Setd5-2XHA mouse ESCs are similar to those 
of wildtype mouse ESCs, we first examined Setd5 levels during RA-induced differentiation of 
Setd5-2XHA mouse ESCs. Quantitative RT-PCR by using HA-specific primers showed the Setd5 
mRNA levels were increased after RA treatment (Figure 9A). We next examined the effect of 
SETD5 knockdown on RA-induced differentiation of SETD5-2XHA mouse ESCs. The 
knockdown of SETD5 was confirmed by quantitative RT-PCR using HA-specific primers (Figure 
9B). RA-induced differentiation of Setd5-2XHA mouse ESCs were inhibited upon SETD5 
depletion (Figure 9C). We further examined the protein level of pluripotent factors (OCT4 and 
NANOG) and neuronal markers (NESTIN and PAX6) by immunoblotting and 
immunofluorescence (Figure 9E). As in WT mouse ESCs, OCT4 and NANOG proteins levels in 
Setd5-2XHA mouse ESCs after RA treatment were less reduced in SETD5-depleted cells than in 
shLuc-treated cells (Figures 9D and 9E). The RA-mediated induction of NESTIN and PAX6 
levels in Setd5-2XHA mouse ESCs, as in WT mouse ESCs, was reduced by SETD5 knockdown 
(Figures 9D and 9E).  These results indicated that Setd5-2XHA mouse ESCs behave as WT 
mouse ESCs. 
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Figure 9. SETD5 depletion also inhibits RA-induced differentiation of Setd5-2XHA knock-
in mouse ESCs 
(A) Analysis of relative mRNA level of Setd5 in Microscopic and AP staining images of shLuc-
treated and two SETD5-depleted (shSETD5-1 and shSETD5-5) mouse ESCs in different stage of 
RA-induced mouse ESC differentiation. mouse ESCs by using HA-specific primers before (ES) 
and after RA-induced mouse ESC differentiation (RA). (B) Analysis of relative mRNA expression 
level of Setd5 between shLuc-treated and two SETD5-depleted (shSETD5-1 and shSETD5-5) 
Setd5-2XHA knock-in mouse ESCs by using HA-specific primers. (C) Microscopic images of 
shLuc-treated and two SETD5-depleted (shSETD5-1 and shSETD5-5) Setd5-2XHA knock-in 
mouse ESCs after RA-induced mouse ESC differentiation. (D) Western blot analysis of HA-
SETD5, Oct4, Nanog, NESTIN and -actin protein levels between shLuc-treated and two 
SETD5-depleted (shSETD5-1 and shSETD5-5) Setd5-2XHA knock-in mouse ESCs before (ES) 
and after RA-induced mouse ESC differentiation (RA). (E) Immunofluorescence staining with 
DAPI, anti-HA, anti-PAX6, anti-NESTIN, and anti-OCT4 between shLuc-treated and SETD5-
depleted (shSETD5-1) Setd5-2XHA knock-in mouse ESCs after RA-induced mouse ESC 
differentiation. Data are presented as the mean ± SD of three independent experiments. P < 0.05 
(*), P < 0.01 (**), and P < 0.001 (***). 
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2.3.5 Setd5-2XHA was recruited to RA Responsive Element (RARE) after RA treatment 
To determine whether SETD5 directly regulates RA-mediated induction of Hoxa1-2 and 
Nestin, we performed quantitative ChIP using SETD5-2XHA mouse ESCs. However, our HA-
ChIP results showed that SETD5 was not recruited to the promoter regions of Hoxa1-2 or Nestin 
(Figure 10A). Hox genes are responsive to RA and several Hox genes contain RA response 
elements (RARE) (89-92). Moreover, Fujiki et al. showed that MLL5 can bind to RAR- upon 
RA treatment (93). Therefore, we examined the possibility that SETD5 binds to RAR- and is 
recruited to the Hoxa1 RARE region after RA treatment. Our HA-ChIP results showed that 
SETD5 was recruited to Hoxa1 RARE region upon RA treatment (Figure 10A). Moreover, 
SETD5 recruitment at the Hoxa1 RARE region upon RA treatment was abolished by SETD5 
depletion (Figure 10B). To assess whether SETD5 physically interacts with RAR- upon RA 
treatment, we transfected an expression plasmid encoding FLAG-tagged RAR- into HEK 293T 
cells and performed FLAG-immunoprecipitation (FLAG-IP) before and after RA treatment. 
Western blot analysis of the FLAG-IP eluates showed that RAR- interacted with endogenous 
SETD5 upon RA treatment (Figure 10C). 
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Figure 10. Setd5-2XHA is recruited to RA responsive element (RARE) near Hoxa1 after 
RA treatment 
(A) Analysis of SETD5 occupancy at RA responsive element near Hoxa1, Hoxa1 promoter and 
Hoxa2 promoter region by using anti-HA antibody to perform HA-ChIP quantitative PCR in 
Setd5-2XHA knock-in mouse ESCs before (ES) and after RA-induced mouse ESCs 
differentiation (RA). (B) Comparison of SETD5 occupancy at RA responsive element near Hoxa1 
between shLuc-treated and SETD5-depleted (shSETD5-1) Setd5-2XHA knock-in mouse ESCs 
by using ChIP qPCR after RA-induced mouse ESC differentiation. (C) FLAG-tagged RAR- was 
expressed in HEK 293T cells. 48 h after transfection, DMSO or 10 M retinoic acid was added 
to cells and incubated for another 1 h. Total cell lysates were then harvested to perform FLAG-
immunoprecipitation, followed by western blot analysis with anti-SETD5 and anti-FLAG. Data 
are presented as the mean ± SD of three independent experiments. P < 0.05 (*), P < 0.01 (**), and 
P < 0.001 (***). 
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2.3.6 SETD5 contains a SET domain but is catalytically inactive. 
Although SETD5 contains one SET domain near its N-terminus, the catalytic activity of 
SETD5 has not been clearly defined. In an effort to further understand the role of SETD5 in RA-
induced differentiation of mouse ESCs, we sought to determine the catalytic activity and the 
substrate of SETD5. To obtain recombinant SETD5 protein, we cloned FLAG-tagged full length 
SETD5 into a baculoviral expression plasmid, expressed FLAG-tagged SETD5 in Sf9 insect cells, 
and purified recombinant SETD5 protein using FLAG-immunoprecipitation (Figure 11A). We 
then performed an in vitro HMT assay using recombinant SETD5 and four different recombinant 
histone substrates (H2A, H2B, H3 and H4). In this experiment, recombinant MLL4-C protein that 
methylates H3 Lysine 4 was included as a positive control (83). The HMT assay results showed 
that the full length recombinant SETD5 protein did not have any detectable methyltransferase 
activity toward four histone substrates while recombinant MLL4-C robustly methylated 
recombinant H3 (Figure 11B).  
Histone-modifying enzymes isolated from mammalian cells are often more active than 
their recombinant forms isolated from baculoviral expression system. One reason is that histone-
modifying enzymes often associate with other proteins to form functional complexes in which 
some protein components play essential roles in regulating the catalytic activity or substrate 
recognition of the histone-modifying enzymes (27). For example, Ash2L, RBBP5 and WDR5 are 
the core components of the MLL protein complex that are indispensable for the full catalytic 
activity of MLL (94). The histone H3K27 methyltransferase EZH2 associates with Suz12 and 
EED to form the PRC2 complex, and the presence of Suz12 and EED are required for EZH2-
mediated catalytic activity (95,96).  To determine the possibility that SETD5 isolated from 
mammalian cells is catalytically active, we cloned mouse SETD5 into FLAG-tagged expression 
plasmid (FLAG-SETD5), expressed FLAG-SETD5 in HEK293T cells, and isolated FLAG-
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SETD5 eluate using FLAG-IP (Figure 11C). We also generated a SET domain deletion mutant 
(FLAG-SETD5-SET) as a negative control for the HMT assay and isolated FLAG-SETD5-
SET eluate (Figure 11C). Our in vitro HMT assay using recombinant nucleosomes as substrates 
showed that Flag-SETD5 and FLAG-SETD5-SET eluates had similar HMT activities. These 
results indicate that SETD5 does not have a detectable HMT activities and that these HMT 
activities were not from the SET domain of SETD5 (Figure 11D).  
It has been shown that the conserved NHS/CxxPN motif in SET domain is essential for 
the binding of SAM, which is critical for HMT activity. However, the sequence alignment showed 
that the NHS/CxxPN motif in SET domain of SETD5 is not conserved because the aspargine (N) 
and histidine (H) are replaced by two arginine residues (RR) (Figure 3B). To determine whether 
the SET domain of SETD5 interacts with SAM, we cloned the SET domain of SETD5 into a GST 
expression plasmid and purified GST-fusion protein (GST-SETD5-SET) from bacteria. We then 
performed a SAM binding assay by incubating [3H]-labeled-SAM with GST-fusion proteins. 
GST-SETD7 was included as a positive control that can also methylate recombinant H3 (97) 
(Figure 11E). The GST pull down assay of the incubated mixtures showed that GST-SET7 but 
not GST-SETD5-SET interacted with [3H]-labeled-SAM (Figure 11F). These results suggest that 
the non-conserved status of the NHS/CxxPN motif in the SET domain of SETD5 may negatively 
affect the recruitment of the cofactor SAM and thereby result in the inactivity of SETD5. 
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Figure 11. SETD5 does not have detectable catalytic activity. 
(A) Colloidal blue staining of full length recombinant SETD5 protein (rSETD5) isolated from 
SF21 insect cells. (B) In vitro HMT assay for full length recombinant SETD5 protein. 
Recombinant c-terminal end of MLL4 protein (rMLL4-C) was used as a positive control. 
Recombinant H2A, H2B, H3 and H4 were used as substrates. [3H]-SAM was used as methyl 
donor and the HMT activity was detected by autoradiography. (C) Flow chart of experimental 
design to isolate SETD5 complex. (D) Silver staining and in vitro HMT assay for SETD5 complex 
(FLAG-SETD5) and SET domain deletion mutant (FLAG-SETD5-SET). Recombinant 
nucleosomes were used as substrates. [3H]-SAM was used as methyl donor and the HMT activity 
was detected by autoradiography. Antibodies against FLAG and H3 were used for western 
analysis as indicated. (E) In vitro HMT assay for SET domain of SETD5 (GST-SETD5-SET). 
GST-SETD7 was used as a positive control. Recombinant H3 was used as substrates. [3H]-SAM 
was used as methyl donor and the HMT activity was detected by autoradiography. Antibodies 
against GST and H3 were used for western analysis as indicated. (F) Radioactive SAM binding 
assay for SET domain of SETD5 (GST-SETD5-SET). GST-SETD7 was used as a positive control. 
The bound [3H]-SAM was detected by Liquid Scintillation Spectrometry. 
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2.3.7 SETD5 interacts with HCF1  
In an effort to understand how SETD5 regulates RA-induced gene expression without its 
histone-modifying activity, we rationalized that SETD5-interacting proteins play a role in 
SETD5-mediated regulation of RA-induced gene expression, because FLAG-SETD5 IP eluates 
contain other protein bands (Figure 11F).  Therefore, we examined the identity of SETD5-
interacting proteins using mass spectrometry analysis (Figure 12A and B). Results showed that 
FLAG-SETD5 IP eluates contain host cell factor 1 (HCF1) in a one-to-one ratio (112 hits for 
SETD5 and 111 hits for HCF1). Consistent with a previous study by Osipovich et al., mass 
spectrometric results also identified all six components of the PAF1 complex  (PAF1, CDC73, 
CTR9, WDR51, LEO1 and RTF1) and O-linked N-acetylglucosamine transferase (OGT) (78). 
Interestingly, several histone methyltransferases SETD2, SETD1A and KMT2A were also present 
in the FLAG-SETD5 IP eluate (Figure 12B), suggesting that the HMT activity of the SETD5 
complex might result from these enzymes.  
We chose to focus on studying HCF1 because our mass spectrometric results identified 
HCF1 as a protein with the highest and most unique peptide numbers. HCF1 is a transcriptional 
coactivator that plays an important role in cell proliferation and cell cycle regulation (98-100). It 
has been shown that HCF1 interacts with several histone modifying enzymes, including the MLL1 
complex, Sin3-HDAC complex, MLL5 and OGT (101-103). To validate the interaction between 
SETD5 and HCF1, we performed HA-immunoprecipitation (HA-IP) using whole cell lysates 
isolated from wildtype and SETD5-2XHA mouse ESCs. Western blot analysis of IP eluates 
showed that HCF1 was immnuoprecipitated by SETD5-2XHA (Figure 12C). Moreover, analysis 
of the SETD5 protein sequence showed that SETD5 isoform 2 contains the HCF1 binding motif 
(HBM), (D/E)HxY (Figure 12D). These data confirmed that SETD5 interacts with HCF1 in 
mouse ESCs. 
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Figure 12. SETD5 interacts with HCF1 
(A) Analysis of SETD5 complex by silver staining. Nuclear extracts were isolated form HEK293T 
cell expressing either empty vector or FLAG-tagged SETD5 followed by FLAG-IP. FLAG-IP 
eluate was further analyzed by mass spectrometry. The top ranked SETD5-interacting protein 
were labelled as indicated. (B) SETD5-interacting protein and numbers of peptides identified by 
mass spectrometry are listed. (C) HA-IP to confirm the endogenous interaction between SETD5 
and HCF1. Total cell lysates from wildtype and Setd5-2XHA knock-in mouse ESCs were used to 
perform HA-IP. Antibodies against HA and HCF1 were used for western analysis as indicated. (D) 
Diagrammatic representation of mouse SETD5 isoform 1 and SETD5 isoform 2. SETD5 isoform 
2 contains a 19 amino acid insertion at the N-terminal of SETD5. The HCF1 binding motif inside 
the 19 amino acid insertion is labelled in red. 
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2.3.8 Depletion of HCF1 inhibits RA-induced differentiation of mouse ESCs  
To assess whether the SETD5-interacting protein HCF1 acts as a transcriptional 
coactivator of SETD5, we first examined the effect of HCF1 knockdown on RA-induced 
differentiation of mouse ESCs. HCF1 knockdown in V6.5 mouse ESC using two shRNAs against 
HCF1 (shHCF1-1 and shHCF1-5) were confirmed by Western blot analysis (Figure 13A). 
Interestingly, HCF1 knockdown, similar to SETD5 knockdown, impeded morphological changes 
during RA-induced differentiation of mouse ESCs, as also confirmed by AP staining (Figure 13B). 
In line with this, HCF1 depletion also inhibited RA-induced expression of SETD5 target genes, 
including Hoxa1, Hoxa2, Nestin, and Pax6 (Figure 13C). These results indicate that HCF1 acts 
as a transcriptional co-activator of SETD5 in mouse ESCs.  
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Figure 13. Depletion of HCF1 inhibits mouse ESC differentiation 
(A) Western blot analysis of HCF1 and -actin (loading control) protein levels between shLuc-
treated and two HCF1-depleted (shHCF1-1 and shHCF1-5) mouse ESCs. (B) Microscopic and 
AP staining images of shLuc-treated and two HCF1-depleted (shHCF1-1 and shHCF1-5) mouse 
ESCs in different stage of RA-induced mouse ESC differentiation. AP staining was performed 5 
days after retinoic acid treatment. (C) Analysis of relative mRNA level of Oct4, Nanog, Hoxa1, 
Hoxa2, Nestin and Pax6 between shLuc-treated and two HCF1-depleted (shHCF1-1 and shHCF1-
5) mouse ESCs in different stage of RA-induced mouse ESC differentiation. Data are presented 
as the mean ± SD of three independent experiments. P < 0.05 (*), P < 0.01 (**), and P < 0.001 
(***). 
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2.3.9 HCF1 is recruited to Hoxa1 RARE region upon RA treatment 
Since SETD5 was recruited to the Hoxa1 RARE region upon RA treatment, we assessed 
using ChIP assay whether HCF1 was also localized at the Hoxa1 upon RA treatment. Our ChIP 
results showed that SETD5 and HCF1 were both recruited to the Hoxa1 RARE region upon RA 
treatment (Figure 14A). Moreover, the recruitment of HCF1 at the Hoxa1 RARE region was 
abolished by SETD5 depletion (Figure 14B). These results indicate that HCF1 is recruited to the 
Hoxa1 RARE region in a SETD5-dependent manner during RA-induced differentiation of mouse 
ESCs.  
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Figure 14. HCF1 is recruited by SETD5 to HOXA1 RARE region upon RA treatment 
(A) Analysis of SETD5 and HCF1 occupancy at RA responsive element near Hoxa1and Hoxa1 
promoter by using antibodies against HA and HCF1 to perform ChIP quantitative PCR in Setd5-
2XHA knock-in mouse ESCs before (ES) and after RA-induced mouse ESCs differentiation (RA). 
(B) Comparison of SETD5 and HCF1 occupancy at RA responsive element near Hoxa1 between 
shLuc-treated and SETD5-depleted (shSETD5-1) Setd5-2XHA knock-in mouse ESCs by using 
ChIP qPCR after RA-induced mouse ESC differentiation. Data are presented as the mean ± SD 
of three independent experiments. P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***). 
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2.4 DISCUSSION 
2.4.1 SETD5 and HCF1 in cellular differentiation 
In current study, we showed that the depletion of SETD5 inhibited RA-induced 
differentiation of mouse ESCs. This is in line with the following previous studies that suggest a 
role for SETD5 in development: 1) SETD5 is highly expressed in brain tissue, suggesting a 
functional importance of SETD5 in central nervous system (72), 2) the loss of one copy of SETD5 
is frequently included in deleted regions in 3p25 microdeletion syndrome, intellectual disability 
and autism (79-82,104-108), and 3) Osipovich et al. indicated that Setd5-null mice are embryonic 
lethal and that their embryos exhibit severe defects in neural tube formation (78). Our results 
showed that SETD5 is required for RA-driven mouse ESC differentiation and the RA-induced 
expression of developmentally important genes, such as Hoxa1 and Hoxa2. Therefore, our 
findings may shed light on the molecular mechanism by which the clinical mutations of SETD5 
cause developmental disorders.   
We identified HCF1 as a major SETD5-interacting protein that can be recruited to the 
SETD5-occupied RARE region near Hoxa1 upon RA treatment. Interestingly, our results showed 
that SETD5 and HCF1 depletion similarly caused defective morphological changes during RA-
induced differentiation of mouse ESCs (Figure 6E and 13B). Moreover, the expression of several 
RA-induced genes, including Hoxa1, Hoxa2, Nestin, and Pax6, was commonly inhibited by 
SETD5 and HCF1 depletion (Figure 7A and 13C). Such similar effects between SETD5 and 
HCF1 knockdown on mouse ESC differentiation indicate that they have similar functions during 
mouse ESC differentiation. This is further supported by several clinical reports implicating that 
loss-of-function mutations in both SETD5 and HCF1 are linked to neurodevelopmental disorders 
(109-111). Our results, together with other reports, indicate that HCF1 acts as a transcriptional co-
activator of SETD5 during mouse ESC differentiation. 
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2.4.2 SETD5 is catalytically inactive but functional  
Based on the phylogenetic analysis, Mas-y-Mas et al. proposed that MLL5, SETD5, the 
yeast protein SET3 and the Drosophila protein UpSET should belong to the same subfamily of 
SET domain-containing proteins (75). In fact, their SET domains are highly conserved although 
they are distinct from SET domains in other MLL family members, and the aspargine (N) and 
histidine (H) residues in NHS/CxxPN motif in the SET domains are all replaced by two arginines 
(RR). In the current study, our in vitro HMT assay using purified recombinant SETD5 and SETD5 
complex showed no intrinsic catalytic activity for SETD5. Moreover, our sequence analysis and 
SAM binding assay indicate that the lack of a conserved NHS/CxxPN motif in the SET domain 
of SETD5 may cause its inability to bind cofactor SAM. These results are in line with several 
previous studies showing that MLL5, SET3, and UpSET are all catalytically inactive (75,112,113). 
Although SETD5 and other family members have no intrinsic catalytic activity, several 
functional studies still indicate their roles in regulating development. For example, the knockout 
mice of MLL5 showed partial lethality and exhibited multiple hematopoietic defects (76). SETD5 
knockout mice are embryonic lethal (78). Deletion of set3 in yeast results in reduced ascus 
formation (112). Flies with UpSET homozygous mutation are viable but females with mutations 
are sterile because of severe defects in oogenesis (113). It is likely that developmental gene 
regulation by MLL5, SET3, and UpSET, despite their lack of catalytic activity, can be mediated 
by protein-protein interactions. Indeed, MLL5 associates with HCF1 to regulate E2F1-responsive 
gene expression (103). It was also reported that MLL5 regulates H3K4 methylation status through 
inhibiting the H3K4 demethylase LSD1 to alter target gene expression (76,77). Both set3 and 
UpSET have been shown to form protein complexes with histone deacetylases to regulate gene 
expression (112,113). Our results showed that SETD5 interacts with HCF1 and that both proteins 
co-activate SETD5 target genes. In addition, our MS analysis showed that SETD5 co-
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immunoprecipitates with two H3K4 methyltransferases, SETD1A and KMT2A (MLL1) (Figure 
12B). The interaction between SETD5 and these H3K4 methyltransferases may be either direct 
or mediated by HCF1 because HCF1 has been shown to interact with several histone modifying 
enzymes, including SETD1A and MLL1 complexes (101,102). Nevertheless, it is possible that 
SETD5 indirectly affects histone methylation status, because the purified SETD5 complex 
(FLAG-SETD5 IP eluate) showed in vitro HMT activity toward recombinant nucleosomes 
(Figure 11F) and the FLAG-SETD5-SET (SET deletion) IP eluates also showed similar HMT 
activity to that of the wildtype SETD5 complex (Figure 11F). Furthermore, we showed that 
SETD5 interacts with RAR- after RA treatment and recruits HCF1 to the Hoxa1 RARE (Figure 
14). Taken together, our findings suggest that SETD5 functions as an adaptor protein to regulate 
gene expression via the interaction with HCF1, RAR- and other H3K4 methyltransferase, such 
as SETD1A and KMT2A. 
 
2.4.3 SETD5 and neurodevelopmental disorders 
Several clinical reports showed the connection between SETD5 and 3p25 microdeletion 
syndrome (Figure 15A). 3p25 microdeletion syndrome is a rare chromosomal disorder that shows 
multiple symptoms including growth retardation, microcephaly, facial dysmorphia, seizures, 
congenital heart disease, and intellectual disability. Individuals with 3p25 microdeletion have one 
intact allele of chromosome 3 while the short arm of the other allele has an interstitial deletion 
(79,80). Recently, a clinical case study first suggested that the SETD5 gene is located in the region 
of 3p25 microdeletion (81). Grozeva et al. further reported that de novo loss-of-function mutations 
in SETD5 may be linked to intellectual disability (82,104). In line with these studies, several other 
reports further indicate that SETD5 is a candidate gene to cause 3p25 microdeletion syndrome 
and intellectual disability (105-107). In addition, Pinto et al. has shown that both copy-number 
60 
 
variation (CNV) and single-nucleotide variation of SETD5 occur in autism spectrum disorder 
(ASD) patients, suggesting SETD5 as an ASD candidate gene (108). Taken together, these studies 
strongly suggest that SETD5 plays an important role in regulating embryogenesis and neuronal 
development.  
Most, if not all, SETD5 mutations lead to premature stop codons and generate truncated 
SETD5 proteins. Interestingly, such mutations are all located after the SET domain (Figure 15B). 
Therefore, truncated SETD5 proteins likely contain an intact SET domain, suggesting that the 
function of the SET domain of SETD5 is dispensable. It is possible that the truncated SETD5 may 
lose the ability to associate with some SETD5-interacting proteins, leading to dysregulation of 
SETD5 target genes and subsequently abnormal differentiation and development.  
 
61 
 
 
Figure 15. De-novo loss-of-function mutations in SETD5 
(A) SETD5 is located in the critical region of chromosome 3p25 microdeletion syndrome. Each 
red bar shows the interstitial deletion on the chromosome 3 from the individual with 3p25 
microdeletion syndrome. The overlap region is highlighted by light grey. (B) Diagrammatic 
representation individuals with de-novo loss-of-function mutations in SETD5 reported by 
Grozeva et al. (82). The numbers indicate the amino acid position where the mutations occur. 
62 
 
2.4.4 The regulation of Hox genes by SETD5 
The Homeobox (Hox) genes exist in four genomic clusters (HoxA to HoxD) and encode 
transcriptional factors that play important roles in determining the anterior-posterior axis during 
embryogenesis and development (114). The expression pattern of Hox genes show spatial and 
temporal co-linearity (in 3’ to 5’ order) during embryogenesis. Specifically, the 3’ end of Hox gene 
clusters are expressed in the anterior segments while the 5’ end of Hox gene clusters are expressed 
in the posterior segments (115). For example, the 3’ end of Hox genes, such as Hoxa1, Hoxa2, 
Hoxb1 and Hoxd1, that are essential for neurogenesis of brain are located in the anterior segments 
(116). Hox gene expression is also regulated in ESC differentiation. Hox genes are 
transcriptionally repressed and undetectable in ESCs. Interestingly, most of the Hox genes clusters 
in ESCs are decorated simultaneously by so-called bivalent domains (repressed but activatable 
states) containing both active H3K4me3 marks and repressive H3K27me3 marks (117). During 
RA-induced ESC differentiation, the expression of Hox genes is highly induced and many bivalent 
Hox promoters lose H3K27me3 marks while being converted to active promoters containing 
H3K4me3 marks (85). 
In the current study, we demonstrated that SETD5 is recruited to Hoxa1 RARE region 
through the interaction with RAR-. We also showed that the induction of Hoxa1 and Hoxa2 
expression in mouse ESCs by RA was significantly inhibited by SETD5 knockdown. It has been 
shown that Hoxa1 is required for RA-induced differentiation of ESCs into neurons (90). Moreover, 
the induction of ectoderm markers by RA are reduced in Hoxa1 knockout ESCs (118). Therefore, 
it is possible that the dysregulated induction of Hoxa1 and Hoxa2 in SETD5 knockdown during 
RA-driven mouse ESC differentiation contributes to the impaired differentiation phenotype of 
SETD5-depleted cells (Figure 16). 
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Figure 16. A hypothetical model for SETD5-mediated gene regulation 
A proposed model for SETD5-mediated gene regulation. During RA-induced mouse ESCs 
differentiation, SETD5 is recruited to the Hox genes RARE region through interaction with RAR-
. SETD5 further recruits transcriptional coactivator HCF1 to the Hox genes RARE region to 
activate the expression of Hox genes. 
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2.5 PERSPECTIVE AND FUTURE DIRECTIONS 
CRISPR-Cas9 gene editing technology allowed us to generate Setd5-2XHA knock-in 
mouse ESCs. We further utilized this technology to generate Setd5 knockout mouse ESCs to 
strengthen the results for our study. However, when we performed RA-induced mouse ESC 
differentiation, Setd5 knockout mouse ESCs showed no significant defective differentiation 
phenotype (data not shown). These results are not consistent with our RNA interference 
experiment which showed that depletion of SETD5 inhibited the RA-induced mouse ESC 
differentiation. Interestingly, we observed that our Setd5-2XHA knock-in mouse ESCs showed 
multiple bands when we performed western by using HA antibody. This result indicates that there 
are multiple isoforms for SETD5 protein in V6.5 mouse ESCs. Our Setd5 knockout mouse ESCs 
were generated by targeting 1st or 4th exons of Setd5. Therefore, we suspected that other functional 
SETD5 isoforms may still exist in Setd5 knockout mouse ESCs which may explain why our Setd5 
knockout mouse ESCs showed no defective differentiation phenotype. We can further generate 
Setd5 knockout mouse ESCs by targeting two separated exons and perform differentiation assays 
to examine the phenotype and to further determine the functions of other SETD5 isoforms and 
their expression in mouse ESCs. 
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CHAPTER 3  
PRMT7-MEDIATED REPRESSION OF MIR-221 IS 
REQUIRED FOR MAINTAINING OCT4, NANOG AND 
SOX2 LEVELS IN MOUSE EMBRYONIC STEM CELLS 
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3.1 INTRODUCTION 
3.1.1 General background of microRNA 
After the completion of human genome project, researchers were surprised that there are 
only approximately 22,333 protein-coding genes in entire human genome (119,120). The rest of 
DNA sequences were non-protein coding and were once considered junk sequences. In 1993, Dr. 
Rosalind Lee and colleagues discovered a C. elegans gene, lin-4, does not encode protein but can 
generate a pair of functional small RNAs (121). They further showed that these small RNAs have 
antisense complimentary to 3’UTR of lin-14 gene and can negatively regulate lin-14 expression. 
We now know that these small RNAs belong to a class of non-coding RNA called microRNA 
(miRNA). They are single-stranded RNA which are normally 20-24 nucleotide in length and can 
negatively regulate gene expression through post-transcriptional mechanisms (122). 
MicroRNAs will go through a serial maturation process to become single-stranded 
functional RNA (122,123). After transcription by RNA polymerase, miRNA will first form a stem 
loop structure called primary microRNA transcripts (pri-miRNA) (124). Pri-miRNA will further 
be cleaved by the Drosha/DGCR8 microprocessor complex in the nucleus to form precursor 
miRNA (pre-miRNA) of approximately 70 nucleotides in length (125). The cleavage by 
Drosha/DGCR8 microprocessor complex creates a 2- nucleotide overhang in 3’ end of the pre-
miRNA hairpin structure, which can be recognized by Exportin-5 and result in the nuclear 
exportation of pre-miRNA to the cytosol (126,127). In the cytosol, Dicer can cleave the pre-
miRNA hairpin structure into a mature miRNA duplex (128). Dicer, together with TRBP and 
Argonaute-2, uses mature miRNA to induce gene silencing by cleaving mRNAs (129). 
MicroRNAs can negatively regulate gene expression by interacting with 3’ untranslated 
regions (UTR) of target mRNA (130). This interaction is dependent on the complementary pairing 
of miRNA with its target mRNAs. In particular, several studies have shown that the seed sequence 
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of miRNA (nucleotides 2-7 from 5’ end of miRNAs) is important for pairing with its target 
mRNAs (131,132). Mature miRNA can lead to post-transcriptional gene repression through 
Argonaute-2-mediated mRNA degradation, translational repression, and mRNA deadenylation 
(129,133-135). 
 
3.1.2 MicroRNAs regulate ESC stemness and differentiation 
To understand the biological function of miRNA pathways, knockout mice for the genes 
involved in the biogenesis of miRNA have been generated. The knockout mice for Dicer, DGCR8, 
and Argonaute-2 are all embryonic lethal (136-138). The Dicer- and DGCR8-null mouse ESCs 
are both viable but have severe defects in proliferation and differentiation (137,139). These studies 
suggest that proteins associated with miRNA processing play important roles in early 
embryogenesis, development, and ESC maintenance. 
miRNA-mediated regulation of stemness and differentiation often results from changes in 
miRNA levels between ESC state and differentiated state (140,141). Several miRNAs are 
identified as ESC-specific miRNAs that are highly expressed in ESC and significantly decreased 
during differentiation. For example, the mouse miR-290-295 family (human homolog miR-371-
373) is the most abundant miRNAs in mouse ESCs (142). These miRNAs have been shown to 
target the cell cycle inhibitor p21 (Cdkn1a) to promote G1/S cell cycle transition in ESCs (143). 
This may partially explain why ESCs can rapidly proliferate. In contrast to ESC-specific miRNAs, 
there are groups of differentiation-associated miRNAs that contribute to ESC differentiation and 
early development processes by targeting the pluripotent factor network. For example, miR-27a, 
miR-24, and let-7 have been identified as differentiation-associated miRNAs that are induced 
during ESC differentiation and directly target pluripotent factors (e.g., Oct4 and Foxo1) or signal 
transducers (gp130 and smad) to inhibit ESC pluripotency (144). 
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The expression patterns of miRNAs can be highly cell type-specific and are important in 
regulating cellular differentiation and development (145-147). It has been shown that the 
expression of miRNAs is regulated by several different mechanisms, including transcriptional 
factors, epigenetic regulation, and post-transcriptional regulation (148,149). Dysregulation of 
miRNAs can lead to cancer or other human diseases (150,151). For example, the repression of 
miRNA expression by DNA hypermethylation at certain miRNA promoters (e.g. miR-124, miR-
34,miR-9 and miR-200 family) has been shown in various type of cancers (152,153). 
 
3.1.3 General background of protein arginine methylation 
Protein arginine methylation is a post-translational modification mediated by a family of 
enzymes called protein arginine methyltransferases (PRMTs) and has been linked to various 
cellular processes, including signal transduction, DNA repair, RNA processing, transcriptional 
regulation, and subcellular transport (154). Three different types of arginine methylation occurs 
on arginine residues in eukaryotes: NG-monomethylarginine (MMA), -NG, NG-dimethylarginine 
(asymmetric DMA), and -NG, N’G-dimethylarginine (symmetric DMA) (32,154). (Figure 1B) 
Arginine is a positively-charged amino acid. The addition of methyl groups on the arginine side 
chain does not change the charge but increases the hydrophobicity of the arginine residue and 
creates a binding motif for protein-protein interaction (154-156). For example, the tudor domain 
can specifically bind to methylated arginine through their aromatic cage. Several tudor domain-
containing proteins, including SND1 and TDRD1, have been shown to interact with methyl 
arginine and to serve as reader proteins to regulate downstream cellular process (157). 
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3.1.4 Protein arginine methyltransferase 
At least nine protein arginine methyltransferases (PRMT1-9) have been identified in 
mammals (32). These enzymes can all use S-adenosyl methionine (AdoMet) as a cofactor and 
transfer methyl groups from AdoMet to the arginine residue of target protein (158). PRMTs can 
be further classified into three different subtypes depending on their arginine methylation products. 
Type I PRMTs, including PRMT1, 2, 3, 6, 8 and PRMT4/CARM1, catalyze arginine mono-
methylation and asymmetric di-methylation. Type II PRMTs, such as PRMT5 and PRMT9, 
catalyze arginine mono-methylation and symmetric di-methylation. Type III PRMT only 
catalyzes arginine mono-methylation and PRMT7 is the sole member of this type (32,154,159). 
In addition, we and others additionally showed that PRMT7 represses gene expression by 
indirectly establishing symmetric dimethylation at H4R3 (H4R3me2s) (83,85,160,161). 
 
3.1.5 Rationale 
We previously reported that protein arginine methyltransferase 7 (PRMT7), a 
transcriptional co-repressor, is essential for maintaining mouse ESC stemness. In the same study, 
we showed that PRMT7 maintains mouse ESC stemness, at least in part, by repressing the 
expression of the miR-24-2 gene (i.e., miR-24-3p and miR-24-2-5p) (85). We also characterized 
miR-24-3p and miR-24-2-5p as anti-stemness miRNAs that directly inhibit the expression of the 
major pluripotent factors Oct4, Nanog, Sox2, Klf4, and c-Myc. We further showed that miR-24-
3p and miR-24-2-5p levels are increased during mouse ESC differentiation and are highly 
upregulated by PRMT7 knockdown (85). In our effort to discover new anti-stemness miRNAs, 
we re-analyzed our previous miRNA expression profile data to determine which miRNAs in 
mouse ESCs are highly upregulated by PRMT7 knockdown. In the present study, we found that 
miR-221-3p and miR-221-5p are novel anti-stemness miRNAs that target the 3’ untranslated 
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regions (3’UTRs) of the major pluripotent factors Oct4, Nanog, and Sox2. Our results also 
revealed that negative regulation of miR-221-3p and miR-221-5p by PRMT7 is necessary to 
maintain ESC pluripotency. 
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3.2 MATERIALS AND METHODS 
3.2.1 Antibodies, plasmids, and other reagents 
Anti-PRMT7 antibodies were purchased from Santa Cruz Biotechnology (SC9882). Anti-
Nanog (#61419), anti-Sox2 (#39823), and anti-H4R3me2s (#61187) antibodies were from Active 
Motif. Anti-Oct4 (#2840), anti-c-Myc (#5605), and anti-Klf4 (#4038) antibodies were from Cell 
Signaling. Anti-β-actin antibody (A5441) was from Sigma-Aldrich. Anti-H4R3me1 antibody 
(PA5-27065) was from Thermo Scientific. Anti-H3 antibody (ab1791) was from Abcam. Mouse 
shPRMT7s (shPRMT7-7, TRCN0000097477; shPRMT7-8, TRCN0000097478) in the 
puromycin-resistant PLKO.1 vector were previously reported from this laboratory (85). 
Oligonucleotides used for site-directed mutagenesis, RT-PCR, ChIP-PCR and CRISPR-Cas9 
guide RNAs are listed in Table 2. 
 
3.2.2 Quantitative PCR for miRNA and mRNA expression 
Total RNAs were isolated by using TRIzol RNA Isolation Reagents (Life technology). To 
detect relative mRNA levels, cDNA was synthesized by using iScript cDNA Synthesis Kit 
(BioRad) according to manufacturer’s instruction. Quantitative PCR was performed by using 
CFX384 real-time PCR detection system (BioRad). GAPDH level were used as internal control.  
For miRNA detection, qScript microRNA cDNA synthesis Kit (Quanta Bio) was used to 
synthesize microRNA cDNA. Briefly, total RNAs (1 μg) were used in a poly(A) polymerase 
reaction to add Poly(A) tail to miRNA. Polyadenylated miRNAs were further reverse-transcribed 
with qScript reverse transcriptase to synthesize miRNA cDNA. Quantitative PCR was performed 
and normalized to sno66 to determine relative miRNA levels. 
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Table 2 miR-221 Oligonucleotide sequences. 
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3.2.3 Chromatin Immunoprecipitation (ChIP) assay 
ChIP assay was performed as previously described with small modifications (83). Mouse 
ESCs were first fixed by 1% formaldehyde. Cell pellets were then lysed with ChIP lysis buffer 
and sonicated for 15 min (30 sec on and 30 sec off for 15 cycles) to shear DNA by using Bioruptor 
(Diagenode). Antibodies were added and incubated for overnight at 4 °C. Pre-blocked protein A 
beads were added and incubated for another 1-2 hr to capture protein-DNA complex. The beads 
were then washed once with the following buffers: low-salt buffer, high-salt buffer, LiCl buffer 
and TE buffer. ChIP DNA were then eluted by ChIP elution buffer (1% SDS and 0.1M NaHCO3). 
The eluate were reverse-crosslinked, and ChIP DNA were purify by phenol/chloroform extraction 
method. 
 
3.2.4 Transfections of miRNA mimics and LNA oligonucleotides 
Mouse ESCs (5 x 105 cells) were trypsinized and transferred to 0.4 cm Gene Pulser 
Electroporation Cuvettes (Biorad). Mouse miR-221-3p mimic, miR-221-5p mimic (Ambion) or 
mouse LNA-miR-221-3p and LNA-miR-221-5p (Exiqon) (150 pmole) were added to the cuvettes. 
Electroporation (250 V and 500 µF) were performed by using Gene Pulser Xcell Electroporation 
Systems (Biorad). After electroporation, cells were rested at room temperature for 10 min and 
seeded into 6 cm dishes. 
 
3.2.5 Luciferase reporter assays 
The 3'UTRs of mouse Oct4, Nanog, Sox2, Klf4, c-Myc and Prmt7 genes in pMIR-
REPORT (Ambion) vector have been previously described (85). The predicted miR-221-3p and 
miR-221-5p target sites in the 3’UTRs were mutated by using QuickChange Site-Directed 
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Mutagenesis Kit (Stratagene). The pre-mature miR-221 sequence was synthesized and cloned into 
retroviral-based miRNA expression vector (pMDH1-PKG-miR-221-GFP). To perform luciferase 
assay, pMIR-REPORT vector containing wild type (WT) or mutant 3’UTRs of Oct4, Nanog, Sox2, 
Klf4, c-Myc and Prmt7 and pMDH1-PKD-miR-221-GFP were transfected into HEK293T cells 
with Renilla vector (Promega). After 48h incubation, transfected cells were harvested. Luciferase 
activities were measured using Dual-Luciferase Reporter assay system (Promega) according to 
the manufacturer's instructions. The firefly luciferase activities were normalized to Renilla 
luciferase activities.  
 
3.2.6 CRISPR/Cas9 gene editing 
pSpCas9n(BB)-2A-GFP (PX461) plasmid with nCas9 (D10A nickase mutant) was 
obtained from Addgene. To generate miR-221-null V6.5 mouse ESCs, two guide RNA (sgRNA) 
sequences that target miR-221 (F1: CTGCTGGGTTTCAGGCTACC; F2: 
AGAAATCTACATTGTATGCC) were cloned separately into pSpCas9n(BB)-2A-GFP. sgRNA-
containing plasmids were then transfected into V6.5 mouse ESCs by using Lipofectamine 3000  
(Life technology) according to manufacturer’s protocol. After 48 h incubation, mouse ESCs were 
trypsinized and sorted by GFP signals. GFP-positive mouse ESCs were plated into 96 well plate 
(one cell per well) to obtain single colony. 
3.2.7 Statistical analysis 
The statistical significance between the two groups was analyzed by student’s t-test using 
Prism software (GraphPad Software Inc.). Data are presented as the mean ± standard deviation 
(SD) of at least three independent experiments. P < 0.05 (*), P < 0.01 (**), and P < 0.001(***) 
indicate statistically significant changes. 
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3.3  RESULTS 
3.3.1 The expression of miR-221-3p and miR-221-5p is directly repressed by PRMT7 
In our effort to identify anti-stemness miRNAs, we searched for miRNAs in mouse ESCs 
that are highly upregulated by knockdown of the pluripotent factor PRMT7 using our previously 
reported microRNA microarray data (85). This search resulted in several candidate miRNAs, and 
miRNA-specific quantitative PCR results showed that miR-221-3p and miR-221-5p in V6.5 ESCs 
were highly up-regulated by two independent PRMT7 shRNAs (shPRMT7-7 and shPRMT7-8) 
(Fig. 17A). The two mature microRNAs, miR-221-3p and miR-221-5p, are from the stem loop 
structure of the precursor miRNA miR-221 (Fig. 17B). The miR-221 gene is located on the X 
chromosome and is overexpressed in many types of cancers (e.g. glioblastomas, breast cancer, 
hepatocellular carcinoma, thyroid papillary carcinoma, and lung cancer) (162). However, little is 
known about anti-stemness function of miR-221.  
It has been generally accepted that PRMT7 monomethylates arginine residues, such as 
H4R3, for gene repression (32). We and others additionally showed that PRMT7 represses gene 
expression by indirectly establishing symmetric dimethylation at H4R3 (H4R3me2s) 
(83,85,160,161). To examine whether miR-221 expression is directly repressed by PRMT7, we 
performed quantitative ChIP experiments. ChIP results showed that PRMT7 occupied a promoter 
region of the miR-221 gene in V6.5 mouse ESCs (Fig. 17C and 17D). We also examined the 
effect of PRMT7 knockdown on monomethylated H4R3 (H4R3me1) and H4R3me2s levels at the 
miR-221 promoter. Our results showed that H4R3me1 and H4R3me2s levels at the miR-221 
promoter were decreased by PRMT7 depletion (Fig. 17E). Together, these results indicate that 
PRMT7 represses the expression of miR-221 by upregulating the repressive histone marks, such 
as H4R3me1 and H4R3me2s, at the miR-221 promoter in V6.5 mouse ESCs. 
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Figure 17. PRMT7 represses the expression of the miR-221 gene by establishing repressive 
arginine methylation.  
(A) Analysis of relative miRNA expression levels between shLuc-treated and two 
PRMT7-depleted (shPRMT7-7 and shPRMT7-8) mouse ESCs using miRNA-specific 
quantitative PCR. (B) The sequences of mature miR-221-5p (Red) and miR-221-3p (Blue) and 
the predicted stem loop structure form of pre-mature miR-221. (C) Schematic representation of 
mouse miR-221 gene localization. S1, S2 and S3 indicate the PCR-amplified regions for ChIP. (D) 
Analysis of relative PRMT7 occupancy at miR-221 promoter using quantitative ChIP. (E) 
Comparison of relative occupancy of PRMT7, H4R3me1, H4R3me2s and total H3 between 
shLuc-treated and PRMT7-depleted mouse ESCz at the miR-221 promoter region in V6.5 mouse 
ESCs. Data are presented as the mean ± SD of three independent experiments. P < 0.05 (*), P < 
0.01 (**), and P < 0.001 (***).  Experiments in Figure 17A were conducted by Sunghun Lee and 
used with his permission. Experiments in Figure 17 D and E were conducted by Shilpa Dhar and 
used with her permission. 
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3.3.2 miR-221 has an anti-stemness function 
To determine whether miR-221-3p and miR-221-5p have an anti-stemness function, we 
examined the effects of miR-221-3p and miR-221-5p mimics on mouse ESC stemness. AP 
staining analysis showed that the transfection of miR-221-3p and miR-221-5p mimics induced 
spontaneous differentiation of V6.5 mouse ESCs (Fig. 18A). Consistent with this, quantitative 
RT-PCR results showed the mRNA levels of the pluripotent factors Oct4, Nanog, Sox2, Klf4, and 
c-Myc were downregulated by miR-221-3p and miR-221-5p mimics (Fig. 18B). We also 
compared the expression levels of miR-221-3p and miR-221-5p between V6.5 mouse ESCs and 
RA-induced differentiated cells. As shown in Fig. 18C, the expression levels of miR-221-3p and 
miR-221-5p were increased upon RA treatment. To further validate the effect of miR-221-3p and 
miR-221-5p mimics on mouse ESC stemness, we used another mouse ESC line R1. Similar to 
results obtained using V6.5 mouse ESCs, the transfection of miR-221-3p and miR-221-5p into 
R1 mouse ESCs induced spontaneous differentiation of R1 ESCs (Fig. 18D) while 
downregulating the major pluripotent factors Oct4, Nanog, Sox2, and Klf4 (Fig. 18E). Our results 
indicate that miR-221 negatively regulates ESC stemness.  
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Figure 18. miR-221 mimics induces mouse ESC differentiation.  
(A & D) Microscopic images of V6.5 (A) and R1 (D) mouse ESCs after the treatment of miR-
221-3p and miR-221-5p mimics for 2 days (2d) or 4 days (4d). BF, bright field; AP; alkaline 
phosphatase staining. (B & E) Analysis of relative Oct4, Nanog, Sox2, Klf4, and c-Myc mRNA 
levels in V6.5 (B) and R1 (E) mouse ESCs after the treatment of miR-221-3p and miR-221-5p 
mimics. R1 cell line was treated with miRNA mimics for 4 days. (C) Relative miR-221-3p and 
miR-221-5p level during RA-induced mouse ESC differentiation. RA 5d, retinoic acid treatment 
for 5 days; RA 10d, retinoic acid treatment for 10 days. Data are presented as the mean ± SD of 
three independent experiments. P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***).  Experiments in 
Figure 18 A, B and C were conducted by Sunghun Lee and used with his permission. 
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3.3.3 miR-221 can target the 3’UTRs of several pluripotent factors, including Oct4, Nanog, 
Sox2, and PRMT7 
Because miR-221-3p and miR-221-5p act as anti-pluripotent miRNAs, we sought to find 
their potential targets. Because Oct4, Nanog, Sox2, Klf4, and c-Myc were downregulated by miR-
221-3p and miR-221-5p mimics and are major pluripotent factors that are critical for both 
stemness maintenance and stemness induction from differentiated cells, we focused on 
determining whether miR-221 targets any of these factors. In addition, we included PRMT7 to 
test the possibility that miR-221 silences its transcriptional repressor PRMT7. The miRNA-
mediated mRNA targeting requires base pairing between a miRNA and its target mRNAs. Such 
base pairing is largely based on the complementarity between the nucleotide positions 2−8 (known 
as seed sequences) in miRNAs and their corresponding mRNA sequences. It has been known that 
the miRNA target sites in mRNAs are present in the 5’ UTRs, open reading frames, and the 3’ 
UTRs (130). Using these criteria, we examined putative target sites for miR-221-3p and miR-221-
5p in Oct4, Nanog, Sox2, Klf4, c-Myc, and Prmt7 genes. Our analysis using several software and 
manual examination suggested that there were putative target sites for miR-221-3p and miR-221-
5p in 3’UTRs of these factors (Fig. 19A and 19B).  
To determine whether miR-221 can directly target Oct4, Nanog, Sox2, Klf4 and c-Myc 
3’UTRs, we transfected both one of luciferase expression plasmids with the 3’UTRs of these 
pluripotent factors along with a miR-221 expression plasmid encoding miR-221-3p and miR-221-
5p  into HEK293T cells. Our results showed that miR-221 expression substantially reduced the 
luciferase activities of Oct4, Nanog, Sox2, Klf4, and Prmt7 3’UTR but not c-Myc 3’UTR (Fig. 
19C), suggesting that miR-221 can directly target Oct4, Nanog, Sox2, Klf4, and Prmt7 3’UTR. 
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Figure 19. miR-221 can target 3’UTRs of the pluripotent factors Oct4, Nanog, Sox2, Klf4 
and Prmt7.  
(A and B) Putative target sites of miR-221-3p (A) and miR-221-5p (B) in 3’UTRs of mouse Oct4, 
Nanog, Sox2, c-Myc, Klf4 and Prmt7. miR-221-3p and miR-221-5p sequences are shown in blue.  
(C) The effect of miR-221 expression on activities of reporter constructs containing Oct4-3’UTR 
(L-Oct4), Nanog-3’UTR (L-Nanog), Sox2-3’UTR (L-Sox2), Klf4-3’UTR (L-Klf4), c-Myc-
3’UTR (L-c-Myc) and Prmt7-3’UTR (L-Prmt7). The miR-221 expression plasmid (pMDH1-
PKG-miR221-GFP) encoding both miR-221-3p and miR-221-5p were transfected with each 
luciferase reporter construct into HEK293T cells. Firefly luciferase activities were normalized to 
the internal transfection control (Renila luciferase). Data are presented as the mean ± SD of three 
independent experiments. P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***). Experiments in Figure 
19 A, B and C were conducted by Sunghun Lee and used with his permission. 
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3.3.4 Both miR-221-3p and miR-221-5p can target 3’UTRs of Oct4, Nanog, Sox2, and Klf4 
while miR-221-5p can also silence Prmt7. 
To determine specific target sites of miR-221-3p and miR-221-5p in Oct4, Nanog, Sox2, 
Klf4, and Prmt7 3’UTR, we individually mutated putative target sites of miR-221-3p and miR-
221-5p in the 3’UTRs in the reporter plasmids (Fig. 20A and 20B). We then co-transfected WT 
or mutant 3’UTR reporter plasmids with a miR-221-3p mimic or miR-221-5p mimic into HEK 
293T cells. Both miR-221-3p and miR-221-5p mimics inhibited the luciferase activities of Oct4, 
Nanog, Sox2, and Klf4 3’UTRs whereas the mutant reporter plasmids resisted the inhibition 
mediated by miR-221-3p and miR-221-5p mimics (Fig. 20C and 20D). Interestingly, miR-221-
5p mimics but not miR-221-3p mimics reduced the reporter activity of Prmt7 3’UTR. Together, 
these results indicate that target sites of miR-221-3p and miR-221-5p are located in Oct4, Nanog, 
Sox2, and Klf4 3’UTRs whereas miR-221-5p but not miR-221-3p targets Prmt7 3’UTR. 
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Figure 20. Both miR-221-3p and miR-221-5p can target 3’UTRs of Oct4, Nanog, Sox2, and 
Klf4 while miR-221-5p can also silence Prmt7.  
(A and B) Schematic representation of luciferase reporter constructs containing Oct4-3’UTR, 
Nanog-3’UTR, Sox2-3’UTR, Klf4-3’UTR, c-Myc-3’UTR and Prmt7-3’UTR. Mutations in 
putative target sites for miR-221-3p (A) and miR-221-5p (B) are shown. The mutated sequences 
are showed in blue. WT, wild type; M, mutant. (C and D) The effect of miR-221-3p and miR-
221-5p mimics on reporter activities of Oct4-3’UTR, Nanog-3’UTR, Sox2-3’UTR, Klf4-3’UTR, 
c-Myc-3’UTR and their mutants. Each WT or mutated reporter constructs were transfected with 
miR-221-3p mimic (C) or miR-221-5p mimic (D) into HEK293T cells. Firefly luciferase 
activities were normalized to the internal transfection control (Renila luciferase). Data are 
presented as the mean ± SD of three independent experiments. P < 0.05 (*), P < 0.01 (**), and P 
< 0.001 (***). Experiments in Figure 20 were conducted by Sunghun Lee and used with his 
permission. 
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3.3.5 The repression of miR-221-3p and miR-221-5p expression is required for maintaining 
mouse ESC stemness 
To determine whether the repression of miR-221-3p and miR-221-5p is necessary for 
maintaining mouse ESC stemness, we examined whether LNA inhibitors of miR-221-3p and miR-
221-5p (LNA-miR-221-3p and LNA-miR-221-5p) delay or inhibit spontaneous differentiation of 
PRMT7-depleted mouse ESCs in which miR-221-3p and miR-221-5p levels are increased by 
PRMT7 depletion (LNA-miRNAs strongly bind to and inhibit their target miRNAs). We treated 
cells with LNA-control, LNA-miR-221-3p, or LNA-miR-221-5p at 5th, 7th, 9th and 11th day after 
transfecting shPRMT7-7 into V6.5 mouse ESCs (Fig. 21A) and examined mouse ESC 
morphology, alkaline phosphatase (AP) staining, protein levels, and mRNA expression. Our 
results showed that the treatment of PRMT7-depleted mouse ESCs with LNA-miR-221-3p or 
LNA-miR-221-5p (as compared to LNA-control) at the 5th and 7th day inhibited spontaneous ESC 
differentiation and restored AP staining (Fig. 21B).  Quantitative RT-PCR results showed that 
expression levels of Oct4, Nanog and Sox2 but not Klf4 in shPRMT7-treated mouse ESCs were 
substantially recovered by both LNA-miR-221-3p and LNA-miR-221-5p at 5th and 7th day (Fig. 
21C and 21D, red bar). Consistent with this, protein levels of these pluripotent factors and 
PRMT7 were increased by the treatment of LNA-miR-221-3p and LNA-miR-221-5p (Fig. 21E). 
In contrast, the transfection of LNA-miR-221-3p or LNA-miR-221-5p at the 9th or 11th day had 
insignificant effects on the differentiation of PRMT7-depleted cells and barely reversed the 
expression of Oct4, Nanog, and Sox2, suggesting that treatment of miR-221 inhibitors at these two 
time points may be too late to inhibit spontaneous differentiation of mouse ESCs by PRMT7 
knockdown. These results indicate that transcriptional repression of miR-221-3p and miR-221-5p 
by PRMT7 is necessary for the maintenance of Oct4, Nanog, Sox2, and Prmt7 levels and the 
stemness of mouse ESCs. 
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Figure 21. PRMT7-mediated repression of miR-221-3p and miR-221-5p levels is 
indispensable for maintaining mouse ESC stemness.  
(A) Schematic representation of the procedure for the treatment of LNA-miR-221-3p and LNA-
miR-221-5p after transfection of shPRMT7-7. (B) Microscopic and AP staining images of 
PRMT7-depleted V6.5 mouse ESCs at the 5th, 7th, 9th, or 11th day after treatment with LNA-
control, LNA-miR-221-5p and LNA-miR-221-3p. (C and D) Analysis of relative mRNA levels 
of Oct4, Nanog, Sox2, c-Myc and Klf4 after treatment of shLuc-treated or PRMT7-depleted V6.5 
mouse ESCs with LNA-miR-221-3p (C) or LNA-miR-221-5p (D) at different time point (5th, 7th, 
and 9th day). (E) Western blot analysis of OCT4, NANOG, SOX2, C-MYC, KLF4, PRMT7 and 
β-ACTIN (loading control) levels after the treatment of shLuc-treated and PRMT7-depleted V6.5 
mouse ESCs with LNA-control, LNA-miR-221-3p and LNA-miR-221-5p. Data are presented as 
the mean ± SD of three independent experiments. P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***). 
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3.3.6 CRISPR-mediated deletion of the miR-221 gene impedes spontaneous differentiation 
of PRMT7-depleted mouse ESCs  
To vigorously confirm that the repression of miR-221-3p and miR-221-5p expression is 
required for mouse ESC stemness, we sought to examine whether miR-221 loss impedes 
spontaneous differentiation of PRMT7-depleted mouse ESCs. We first generated miR-221-null 
mouse ESCs by using a CRISPR-Cas9 strategy that is a powerful tool for genome editing in living 
cells (88). In particular, we employed a double nicking strategy involving two guide RNAs and 
Cas9-D10A nickase (a mutant form of the RNA-guided, double-strand cleaving DNA 
endonuclease Cas9), because this strategy introduces DNA double strand breaks with significantly 
increased specificity around the target region (163). Two 20 bp-long single-guide RNAs (sgRNAs) 
was individually cloned into a Cas9-D10A nickase expression plasmid that was used to target the 
mouse miR-221 gene (Fig. 22A). We transfected these plasmids into V6.5 mouse ESCs and 
screened mouse ESC colonies to obtain miR-221-null mouse ESC clones. Since V6.5 mouse ESCs 
was derived from a male mouse embryo and miR-221 gene is located on the X chromosome, one 
allele of the X chromosome needs to be deleted for the generation of miR-221-null mouse ESCs. 
Genomic PCR results showed that the miR-221 gene was deleted in two clones (miR-221-KO #4 
and miR-221-KO #7) (Fig. 22B). DNA sequencing of genomic PCR products also confirmed the 
knockout of miR-221 (Fig. 22C). Furthermore, miRNA-specific quantitative PCR showed that 
the expression of miR-221-3p and miR-221-5p was undetectable (Fig. 22D). These two miR-221 
knockout clones (miR-221-KO #4 and miR-221-KO #7) were morphologically normal and were 
positively stained by alkaline phosphatase (Fig. 22E), in line with a previous report showing a 
minor effect of miR-221 inhibition on ESC proliferation (164). 
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Figure 22. Generation of miR-221-null V6.5 mouse ESCs by a CRISPR/Cas9 strategy.  
(A)  CRISPR/Cas9 targeting sites for generating miR-221-null V6.5 mouse ESCs. The two guide 
RNA (sgRNA) sequences are underlined. The PAM sequences are labelled in blue. (B)  PCR 
analysis of WT and miR-221-null V6.5 mouse ESCs by using primers flanking the miR-221 
deletion region. The PCR band size for WT miR-221 is predicted to be 500 bp. (C) DNA 
sequencing chromatograms for miR-221-KO #4 and miR-221-KO-#7. (D) Analysis of relative 
miRNA levels between WT and miR-221-null V6.5 mouse ESCs (Clone #4 and #7) by using 
miRNA-specific quantitative PCR. (E) Microscopic and AP staining images of WT, miR-221-KO 
#4 and miR-221-KO #7 mouse ESCs. BF, bright field; AP; alkaline phosphatase staining. Data 
are presented as the mean ± SD of three independent experiments. P < 0.05 (*), P < 0.01 (**), and 
P < 0.001 (***). 
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3.3.7 miR-221 loss blocks spontaneous differentiation of PRMT7-depleted mouse ESCs. 
To determine whether miR-221 loss blocks spontaneous differentiation of PRMT7-
depleted mouse ESCs, we knocked down PRMT7 in miR-221-null ESCs (miR-221-KO #4 and 
miR-221-KO #7). miR-221 loss inhibited spontaneous differentiation of PRMT7-depleted mouse 
ESCs, as evident by mouse ESC morphology as well as positive AP staining (Fig. 23A). 
Consistent with this, miR-221 loss restored Oct4, Nanog, and Sox2 mRNA levels in PRMT7-
depleted mouse ESCs (Fig. 23B). Because we previously showed that PRMT7 knockdown 
induced endoderm (e.g., Afp, Foxa2, and Sox17), mesoderm (e.g., Bmp2) and 
mesoderm/endoderm (e.g., Gata4 and Gata6) markers (85), we examined whether miR-221 loss 
prevents their induction by PRMT7 knockdown. In fact, miR-221 loss inhibited shPRMT7-
mediated induction of Afp, Foxa2, Sox17, Bmp2, Gata4 and Gata6 (Fig. 23C). Together, our 
results indicate that the repression of miR-221-3p and miR-221-5p is critical for maintaining 
mouse ESC stemness. 
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Figure 23. miR-221 loss blocks spontaneous differentiation of PRMT7-depleted mouse ESCs.  
(A) Microscopic and AP-staining images of shLuc-treated and PRMT7-depleted WT and miR-
221-null V6.5 mouse ESCs. BF, bright field; AP; alkaline phosphatase staining. (B) Comparison 
of relative mRNA level of Prmt7, Oct4, Nanog, Sox2, Klf4, and c-Myc between WT and miR-221-
null V6.5 mouse ESCs after treatment of shLuc or shPRMT7-7. (C) Comparison of relative 
mRNA level of Afp, Foxa2, Sox17, Bmp2, Gata4, and Gata6 between WT and miR-221-null V6.5 
mouse ESCs after treatment of shLuc or shPRMT7-7.  Data are presented as the mean ± SD of 
three independent experiments. P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***). 
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3.4 DISCUSSION 
3.4.1 The anti-stemness function of miR-221 
miR-221 is overexpressed in various types of cancers. Several targets of miR-221 have 
been identified (162). For example, miR-221 directly targets the cell cycle inhibitor p27 (Kip1) 
and positively affects proliferation potential in prostate cancer (165). miR-221 also targets the 
tumor suppressor and cell cycle inhibitor p57 (CDKN1C) in hepatocellular carcinoma (166). 
Garofalo et al. showed that miR-221 targets the tumor suppressors PTEN and TIMP3 to enhance 
tumorigenicity of non-small cell lung cancer and hepatocellular carcinoma  (167). Overexpression 
of miR-221 in several cancers is linked to the resistance to various cancer therapies in addition to 
growth advantage of cancer cells (162). For instance, expression of miR-221 is increased in 
several chemo-resistant cancer cells (168,169). For these reasons, miR-221 is considered an 
oncomiR that plays an important role in cancer development, and the inhibition of miR-221 in 
combination with other cancer treatments may be relevant to a new therapeutic strategy for cancer 
treatment (170,171). Distinct from these studies, results reported here uncover that miR-221 has 
an anti-stemness function to enhance the differentiation of mouse ESCs. 
The anti-stemness and pro-differentiation function of miR-221-3p and miR-221-5p are 
supported by several lines of evidence. In fact, we showed that transfection of miR-221-3p or 
miR-221-5p mimics in two different ESC cell lines induced ESC differentiation and that the loss 
of the miR-221 gene almost completely inhibited spontaneous differentiation of PRMT7-depleted 
mouse ESCs. We also found that the expression levels of miR-221-3p and miR-221-5p were low 
in mouse ESCs as compared to differentiated somatic cells (3T3 fibroblasts) (data not shown) and 
were increased during RA-induced differentiation. In line with our findings, miR-221 is 
upregulated in fully differentiated neurons (172) and plays a role in neuron differentiation (173). 
The differentiation of ESCs requires both downregulation of pluripotent factors and upregulation 
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of lineage-specific markers (14,174). In support of this, our results showed that miR-221 loss not 
only recovers the expression of the pluripotent markers (e.g., Oct4, Nanog, and Sox2) but also 
downregulates the expression of mesoderm and endoderm markers (Fig. 23). 
There are several ESC-specific miRNAs that target anti-stemness genes (140,141). For 
example, the mouse miR-290-295 family members (human homolog miR-371-373) are among 
the most abundant miRNAs in mouse ESCs (142) and target the cell cycle inhibitor p21 (Cdkn1a) 
to promote G1/S cell cycle transition and rapid proliferation of ESCs (143). In contrast to pro-
stemness miRNAs, certain miRNAs inhibit ESC stemness and induce cell differentiation by 
targeting pluripotent networks. For example, let-7, miR-21, miR-134, and miR-145 are anti-
stemness miRNAs that target pluripotent factors, such as Oct4, Nanog, Sox2, c-Myc, Sal4, Lin28, 
and Klf4 (175-178). In the present study, our reporter assay in combination with mutagenesis 
indicate that miR-221 miRNAs can target the 3’ UTRs of the major pluripotent factors Oct4, 
Nanog, Sox2, Klf4, and Prmt7. Moreover, LNA-miRNA-mediated inhibition or CRISPR-
mediated deletion of miR-221-3p and miR-221-5p restored the expression of Oct4, Nanog, Sox2, 
and Prmt7 in PRMT7-depleted mouse ESCs. These findings indicate that miR-221 acts as an anti-
stemness miRNA by targeting mRNAs of multiple pluripotent genes, including at least Oct4, 
Nanog, Sox2, and Prmt7.  
 
3.4.2 PRMT7 negatively regulates the expression of miR-221 
It has been shown that the miR-221 gene is transcriptionally regulated by several 
transcriptional factors. For example, ERα binds to the miR-221 promoter to repress miR-221 
expression, consistent with the overexpression of miR-221 in ER-negative breast cancer (179). 
The expression of miR-221 in breast cancer is positively regulated by EGFR-RAS-RAF-MEK-
ERK2-FOSL1 axis, and FOSL1 activates miR-221 expression through its interaction with the 
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miR-221 promoter (180). Fornari et al. showed that p53 can regulate miR-221 levels in 
hepatocellular carcinoma (181). In the current study, our results indicate that PRMT7 binds to the 
miR-221 promoter and increases the repressive epigenetic marks H4R3me1 and H4R3me2s to 
downregulate miR-221 expression. Thus, our findings provide a new miR-221-regulatory 
mechanism in which the expression of miR-221 is epigenetically repressed by the histone arginine 
methyltransferase PRMT7 in mouse ESCs.  
miR-221-5p targets its own repressor PRMT7 besides the well-known pluripotent factors 
Oct4, Nanog, and Sox2 (Figs. 20D), and PRMT7 represses the miR-221 gene by establishing 
repressive arginine methylation marks (Fig. 17). Therefore, there is a mutual antagonistic 
relationship between miR-221-5p and PRMT7. Interestingly, we previously reported an additional 
antagonistic relationship that is formed by PRMT7 and miR-24-3p/miR-24-2-5p (85). Although 
PRMT7 represses both miR-221 and miR-24-2 genes in mouse ESCs, results reported here showed 
that CRISPR-mediated deletion of the miR-221 gene alone was enough to block spontaneous 
differentiation of PRMT7-depleted mouse ESCs. Thus, it is plausible that PRMT7-mediated 
repression of the miR-221 gene may play a more predominant role in maintaining mouse ESC 
stemness than PRMT7-mediated repression of the miR-24-2 gene, although both miR-221 and 
miR-24-2 might be required for spontaneous differentiation of PRMT7-depleted mouse ESCs. 
Perhaps, this could be addressed by future experiments involving both CRISPR-mediated miR-
24-2 deletion and PRMT7 knockdown. 
 
3.4.3 Summary 
In summary, our results show that miR-221-3p and miR-221-5p can target the major 
pluripotent factors Oct4, Nanog, and Sox2 in mouse ESCs, indicating an anti-stemness and pro-
differentiation role for miR-221-3p and miR-221-5p. Because our results also uncovered that 
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PRMT7 epigenetically represses the expression of miR-221-3p and miR-221-5p in mouse ESCs 
and that miR-221-5p can target the expression of Prmt7, it is possible that miR-221-5p and Prmt7 
form a negative feedback loop.  Finally, we provide evidence that PRMT7-mediated repression 
of miR-221-3p and miR-221-5p is necessary for maintaining mouse ESC stemness.  
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3.5 PERSPECTIVE AND FUTURE DIRECTIONS 
In our current study, we showed that PRMT7 represses the expression of miR-221 gene in 
mouse ESCs to maintain the stemness of mouse ESCs. Our results further showed that both miR-
221-3p and miR-221-5p are anti-stemness miRNAs that can target several major pluripotent 
factors in mouse ESCs to induce spontaneous differentiation. Furthermore, we also found that the 
expression levels of miR-221 is low in mouse ESCs as compared to differentiated somatic cells 
and were increased during RA-induced differentiation. It should be interesting to further 
determine whether we can target miR-221 to generate induced pluripotent stem cells (iPSCs). This 
could be addressed by future experiments to inhibit the expression of miR-221 and determine the 
efficiency of iPSCs generation. 
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